Official Protocol Title:  
NCT number:  [STUDY_ID_REMOVED] 
Document Date:  26-OCT-2017A Phase 3, Double-Blind, Randomized, Multicenter, Controlled 
Study to Evaluate the Immunogenicity, Safety, and Tolerability of 
VARIVAX™ Passage Extension 34 (PE34) Process Administered 
Concomitantly with M-M-R™ II
Product:   V210 1
Protocol/Amendment No.: A03-[ADDRESS_205271]-2017
ConfidentialTHIS PROTOCOL AMENDMENT AND ALL OF THE INFORMATION RELATING 
TO IT ARE CONFIDENTIAL AND PROPRIETARY PROPERTY OF MERCK 
SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC., 
WHITEHOUSE STATION, NJ, U.S.A.
SPONSOR:
[COMPANY_006] Sharp & Dohme Corp., a subsidiary  of [COMPANY_006] & Co., Inc. 
(hereafter referred to as the Sponsor or [COMPANY_006])
One [COMPANY_006] Drive
P.O. Box [ADDRESS_205272] information can be found in the 
Investigator Trial File 
Binder (or equivalent) .
TITLE:
A Phase 3, Double- Blind, Randomized, Multicenter, Controlled Study  to Evaluate the 
Immunogenicit y, Safet y, and Tolerability  of VARI VAX™ Passage Extension 34 (PE34) 
Process Administered Concomitantly  with M -
M-R™ II
IND NUMBER:   [ADDRESS_205273] NUMBER:   Not a pplicable 
  04S63N 
  055D6R
Product:   V210 2
Protocol/Amendment No.: A03-[ADDRESS_205274]-2017
ConfidentialTABLE OF CONTENTS
SUMMARY OF CHANGES .................................................................................................. 9
1.0 TRIAL SUMMARY .................................................................................................. 11
2.0 TRIAL DESIGN ........................................................................................................ 11
Trial Design ........................................................................................................... 11 2.1
Trial Diagram ........................................................................................................ 12 2.2
3.0 OBJECTIVE(S) & HYPOTHESIS(ES) .................................................................. 13
Primary Objective(s) & Hypothesis(es) .............................................................. 13 3.1
Secondary Objective(s) & Hypothesis(es) ........................................................... 14 3.2
4.0 BACKGROUND & RATIONALE .......................................................................... [ADDRESS_205275] Population .................................... 15 4.2.1
Rationale for Dose Selection/Regimen ............................................................... 15 4.2.2
Rationale for Endpoints ...................................................................................... 16 4.2.3
Immunogenicit y Endpoints .......................................................................... 16 [IP_ADDRESS]
Safety  Endpoints .......................................................................................... 16 [IP_ADDRESS]
Future Biomedical Research ........................................................................ 17 [IP_ADDRESS]
Benefit/Risk ........................................................................................................... 17 4.3
5.0 METHODOLOGY ................................................................................................... 17
Entry Criteria ........................................................................................................ 17 5.1
Diagnosis/Condition for Entry  into the Trial ...................................................... [ADDRESS_205276] Deferment Criteria (Before Vaccination 2) .................................... 20 [IP_ADDRESS]
Criteria for Excluding Subjects from Receiving Vaccination 2 .................. 21 [IP_ADDRESS]
Trial Vaccination(s) .............................................................................................. 22 5.2
Dose Selection .................................................................................................... 22 5.2.1
Dose Selection (Preparation) ....................................................................... 22 [IP_ADDRESS]
Timing of Dose Administration .......................................................................... [ADDRESS_205277]:   V210 3
Protocol/Amendment No.: A03-[ADDRESS_205278]-2017
ConfidentialTrial Blinding...................................................................................................... 23 5.2.3
Randomization or Vaccine Allocation ................................................................ 23 5.3
Stratification .......................................................................................................... 23 5.4
Concomitant Medications/Vaccinations (Allowed and Prohibited) ................. 23 5.5
Rescue Medications & Supportive Care ............................................................. 25 5.6
Diet/Activity/Other Considerations ..................................................................... [ADDRESS_205279] Withdrawal/Discontinuation Criteria ................................................... [ADDRESS_205280] Replacement Strategy ............................................................................. 26 5.9
Beginning and End of the Trial ........................................................................... 26 5.10
Clinical Criteria for Early Trial Termination ................................................... 26 5.11
6.0 TRIAL FLOW CHART ........................................................................................... 27
7.0 TRIAL PROCEDURES ........................................................................................... 29
Trial Procedures ................................................................................................... 29 7.1
Administrative Procedures .................................................................................. 29 7.1.1
Informed Consent ......................................................................................... 29 [IP_ADDRESS]
[IP_ADDRESS].1 General Informed Consent .................................................................... 29
[IP_ADDRESS].2 Consent and Collection of Specimens for Future Biomedical 
Research ................................................................................................ 30
Inclusion/E xclusion Criteria ........................................................................ 30 [IP_ADDRESS]
Subject I dentification Card .......................................................................... 30 [IP_ADDRESS]
Medical History ........................................................................................... 30 [IP_ADDRESS]
Prior and Concomitant Medications Review ............................................... 30 [IP_ADDRESS]
[IP_ADDRESS].1 Prior Medications .................................................................................. 30
[IP_ADDRESS].2 Concomitant Medications ..................................................................... 31
Assignment of Screening Number ............................................................... 31 [IP_ADDRESS]
Assignment of T reatment/Randomization Number ..................................... 31 [IP_ADDRESS]
Trial Compliance (Medication/Diet/Activity )............................................. 31 [IP_ADDRESS]
Distribution of Electronic Vaccination Report Card (eVRC) ...................... 31 [IP_ADDRESS]
Clinical Procedures/Assessments ........................................................................ 32 7.1.2
Vaccine Administration ............................................................................... 32 [IP_ADDRESS]
[IP_ADDRESS].[ADDRESS_205281]:   V210 4
Protocol/Amendment No.: A03-[ADDRESS_205282]-2017
Confidential7.[IP_ADDRESS] Administration of Trial Vaccines ......................................................... 32
[IP_ADDRESS].3 General Precaution for Administration of Vaccine .............................. 33
[IP_ADDRESS].4 Temperature Procedures ....................................................................... 33
[IP_ADDRESS].5 Clinical Follow -up................................................................................ 33
Laboratory  Procedures/Assessments .................................................................. 34 7.1.3
Laboratory  Immunogenicity  Evaluations .................................................... 34 [IP_ADDRESS]
[IP_ADDRESS].1 Blood Sample Collection for Antibody Me asurement ......................... 34
[IP_ADDRESS].2 Detection of IgG Antibody  to VZV (gpELISA) ................................... 34
Future Biomedical Research Samples ......................................................... 35 [IP_ADDRESS]
Other Procedures ................................................................................................ .35 7.1.4
Withdrawal/Discontinuation ........................................................................ 35 [IP_ADDRESS]
[IP_ADDRESS].1 Withdrawal From Future Biomedical Research ................................... 35
[IP_ADDRESS].[ADDRESS_205283] Blinding/Unblinding ....................................................................... 36 [IP_ADDRESS]
Calibration of Critical Equipment ................................................................ 37 [IP_ADDRESS]
Visit Requireme nts.............................................................................................. 37 7.1.5
Screening ...................................................................................................... 37 [IP_ADDRESS]
Vaccination Visits ........................................................................................ 37 [IP_ADDRESS]
Post-trial (Visit 4: Follow -up Visit, and Visit 5: Follow -up Phone Call) ....37 [IP_ADDRESS]
Assessing and Recording Adverse Events .......................................................... 37 7.2
Definition of an Overdose for This Protocol and Reporting of Overdose to 7.2.1
the Sponsor .......................................................................................................... 38
Immediate Reporting of Adverse Events to the Sponsor .................................... 39 7.2.2
Serious Adverse Events ............................................................................... 39 [IP_ADDRESS]
Events of Clinical I nterest ............................................................................ 40 [IP_ADDRESS]
Evaluating Adverse Events ................................................................................. 40 7.2.3
Sponsor Responsibility  for Reporting Adverse Events ...................................... 43 7.2.4
8.0 STATISTICAL ANALYSIS PLAN ........................................................................ 43
Statistical Analysis Plan Summary ..................................................................... 43 8.1
Responsibility for Analyses/In -house Blinding .................................................. 44 8.2
Hypotheses/Estimation ......................................................................................... [ADDRESS_205284]:   V210 5
Protocol/Amendment No.: A03-[ADDRESS_205285]-2017
ConfidentialSafety  Endpoints ................................................................................................ .45 8.4.2
Analysis Populations ............................................................................................. 45 8.5
Immunogenicit y Analysis Populations ............................................................... 45 8.5.1
Per-protocol Population ............................................................................... 45 [IP_ADDRESS]
Full Anal ysis Set .......................................................................................... 46 [IP_ADDRESS]
Safety Anal ysis Population ................................................................................. 46 8.5.2
Statistical Methods ................................................................................................ 47 8.6
Statistical Methods for Immunogenicit y Anal ysis.............................................. 47 8.6.1
Noninferiorit y of Postvaccination 1 VZV Antibody  Response (Primary  [IP_ADDRESS]
Hypothesis 1) ............................................................................................... 47
Noninferiorit y of Postvaccination 1 VZV Antibody  GMT (Primary [IP_ADDRESS]
Hypothesis 2) ............................................................................................... 47
Acceptability  of Immune Response (Primary  Hypothesis 3) ...................... 48 [IP_ADDRESS]
Secondary  Summaries .................................................................................. 48 [IP_ADDRESS]
Statistical Methods for Safety Anal ysis.............................................................. [ADDRESS_205286]/Destruction/Returns and Reconciliation .............................................. [ADDRESS_205287]:   V210 6
Protocol/Amendment No.: A03-[ADDRESS_205288] Records ..................................................................... 59 10.1.2
Confidentialit y of Investigator Information ........................................................ 59 10.1.3
Confidentiality  of IRB/IEC I nformation ............................................................. [ADDRESS_205289] of Abbreviations and Definitions of Terms ................................................. 76 12.5
13.0 SIGNATURES ........................................................................................................... 78
Sponsor's Representative ..................................................................................... [ADDRESS_205290]:   V210 7
Protocol/Amendment No.: A03-[ADDRESS_205291] OF TABLES
Table 1 Trial Vaccinations ................................................................................................. 22
Table 2 Evaluating Adverse Events ................................................................................... 41
Table 3 Analy sis Strategy  for Key  Immunogenicit y Variables ......................................... 50
Table 4 Analy sis Strategy
 for Safety  Parameters ............................................................... 52
Table 5 Differe nces in Incidence of Adverse Event Rates between the Two 
Vaccination Groups That Can be Detected With an ~80% Probability  and a 
Two-
Sided Significance Level of 0.05 Postvaccination 1.................................... 55
Table 6 Differences in Incidence of Adverse Event Rates Between the Two 
Vaccination Groups That Can be Detected With an ~80% Probability  and a 
Two-
Sided Significance Level of 0.[ADDRESS_205292]:   V210 8
Protocol/Amendment No.: A03-[ADDRESS_205293]:   V210 9
Protocol/Amendment No.: A03-[ADDRESS_205294]-2017
ConfidentialSUMMARY OF CHANGES
PRIMARY REASON(S) FOR THIS AMENDMENT:
Section Number (s) Section Title (s) Description of Change (s) Rationale
[IP_ADDRESS] Serious Adverse Events Updated that serious adverse 
events (SAEs) should be reported 
from the time period beginning at 
treatment 
allocati on/randomization  through 
6 months (~180 days) following 
the second vaccination (instead of 
through 14 days [42 days for live 
attenuated vaccines] after each 
vaccination ).The reporting period of SAEs has 
been amended to remain consistent 
with the reporting standards within 
the VARIVAX™ p rogram.
[IP_ADDRESS] Safety  Endpoints Added unsolicited injection- site 
reactions from the eVRC, 
occurring on Days [ADDRESS_205295] s intended to be collected in 
this trial;however, the previous 
version of the protocol did not list 
unsolicited injection -site reactions 
in this section of the protocol.  
This chang e provides consistency 
within the protocol. 
  04S63N 
  055D6R
Product:   V210 10
Protocol/Amendment No.: A03-[ADDRESS_205296]-2017
ConfidentialSection Number (s) Section Title (s) Description of Change (s) Rationale
[IP_ADDRESS].[ADDRESS_205297].
6.0 Trial Flow Chart Clarified that parents/legall y 
acceptable representative should 
not record oral or otic 
temperatures.This change is being made to 
provide clarit y regarding the 
methodology  o f temperature 
assessment by p arents/legall y 
acceptable representatives.[IP_ADDRESS].4 Temperature Procedures
ADDITIONAL CHANGE (S)FOR THIS AMENDMENT:
No additional changes. 
  04S63N 
  055D6R
Product:  V210 11
Protocol/Amendment No.:  A03 -[ADDRESS_205298]-2017
Confidential1.0TRIAL SUMMARY
Abbreviated Title Immunogenicity and Safety of VARIVAX™Passage Extension 34 
(PE34) Process in Children
Sponsor Product Identifiers V210
Varicella virus vaccine live ( Oka/[COMPANY_006] )
Trial Phase Phase 3
Clinical Indication Active immunization for the prevention of varicella in individuals 
12months of age and older
Trial Type Interventional
Type of control Active control without placebo
Route of administration Subcutaneous
Trial Blinding Double -blind
Vaccination Groups Healthy children who are 12 to 23 months of age will be randomized 
to receive 2 doses of either VARIVAX™ Passage Extension 34 
(PE34) process (Group 1) or VARIVAX™ ([ADDRESS_205299] ) (Group 2), each given approximately 3 months apart ,
concomitantly with M -M-R™ II
Number of trial subjects Approx imately 600subjects will be enrolled.
Estimated duration of trial The Sponsor estimates that the trial will require approximately 
18months from the time that written inform ed consent is provided for 
the first subject until the last subject’s last study -related phone call or 
visit. For purposes of analysis and reporting, the overall study ends 
when the Sponsor receives the last serology assay result .
Duration of Participation Each subject will participate in the trial for approximately 9months
from the time the subject/legally acceptable representative signs the 
informed c onsent form through the final contact.
A list of abbreviations used in this document can be found in Section 12. 4.
2.0TRIAL DESIGN
Trial Design 2.1
This is a randomized, comparator -controlled, multi center, double- blind trial to evaluate the 
safet y, tolerabilit y, and immunogenicit y of the VARIVAX™ (varicella virus vaccine live,
Oka/[COMPANY_006] ; V210,[COMPANY_006] )Passage Extension 34 (PE34 )process compared with the 
VARIVAX™ ([ADDRESS_205300] ) in healthy  children who are between 12to 
23months of age .
Approximately  600 subjects will be enrolled. Subjects will be randomized into 1 of 2 
vaccination groups (ratio 1:1) with approximately  300 subjects per group .  Group 1 will 
receive 2doses of VARI VAX™ PE34 process , given concomitantl y with M-M-R™ II
[measles, mumps, and rubella virus vaccine live, [COMPANY_006]] , approximately  3months apart.  Randomization Ratio 1:[ADDRESS_205301]:  V210 12
Protocol/Amendment No.:  A03 -[ADDRESS_205302]-2017
ConfidentialGroup 2 will receive 2 doses of VARIVAX™ ([ADDRESS_205303] ), given 
concomitantly  with M -M-R™ II, approximately  [ADDRESS_205304] (from first visit to last contact) will be 
approximately  [ADDRESS_205305] completed the trial when (1) both 
scheduled trial vaccinations are received, (2) both blood samples have been collected, and 
(3)the [ADDRESS_205306] been collected.
Specific procedures to be performed during the trial, as well as their prescribed times and 
associated visit windows, are outlined in the Trial Flow Chart -Section 6.0. Details of each 
procedure are provided in Section 7 .0–Trial Procedures.
Trial Diagram 2.[ADDRESS_205307]:  V210 13
Protocol/Amendment No.:  A03 -[ADDRESS_205308]-2017
Confidential3.0OBJECTIVE(S) & HYPOT HESIS(ES)
The following objectives will be evaluated in healthy  children aged 12 to 23 months.
Primary Objective(s) & Hypothesis (es) 3.1
1)Objective :  To demonstrate that a single dose of VARIVAX™ PE34 process induces 
varicella -zoster virus (VZV )antibod y responses 6 weeks Postvaccination 1that are 
noninferior to those induced b y VARIVAX™ [ADDRESS_205309] .
The primary  endpoint sfor measuring the VZV antibody  response sarethe response 
rate and the geometric mean titer (GMT) .  The response rate is defined as the 
proportion of subjects with VZV antibod y titer ≥5 glycoprotein enzyme-linked 
immunosorbent assay  (gpELISA) units/mL  6weeks Postvaccination 1among 
subjects who were seronegative to VZV (titers <1.25 gpELISA units/mL ) at baseline .
Hypothese s:
(1)  Six weeks Postvaccination 1, VARIVAX™ PE34 process induces VZV antibody 
responses that are noninferior to those induced by [CONTACT_175993]™ ([ADDRESS_205310] ),as measured b y the response rate .
(The statistical criterion for noninferiority  of the response rate corresponds to the 
lower bound of the 2-sided 95% confidence interval [CI] onthe difference in 
response rates [VARI VAX™ PE34 process minus VARI VAX™ [ADDRESS_205311] ]excluding a decrease of 10 percentage points or more.)
(2)  Six weeks Postvaccination 1, VARIVAX™ PE34 process induces VZV antibody 
responses that are noninferior to those induced by [CONTACT_175993]™ ([ADDRESS_205312] ),as measured b y the GMT .
(The statistical criterion for noninferiority  of the GMT corresponds tothe lower 
bound of the 2-sided 95% CI on the GMT ratio [VARIVAX™ PE34
process /VARIVAX™ [ADDRESS_205313] ]being >0.67.)
2)Objective:   To demonstrate that a single dose of VARIVAX™ PE34 process induces 
an acceptable VZV antibody  response 6 weeks Postvaccination 1.
Hypothesi s:
(3) Six weeks Postvaccination 1, VARIVAX™ PE34 process induces an acceptable 
VZV antibod y response , as measured b y the response rate .
(The statistical criterion for an acceptable antibody  response corresponds to the lower 
bound of the 95% CI for the response rate to VZV in the group receiving 
VARIVAX™ PE34 process being >76.0%.) 
  04S63N 
  055D6R
Product:  V210 14
Protocol/Amendment No.:  A03 -[ADDRESS_205314]-2017
ConfidentialSecondary Objective(s) & Hyp othesis(es) 3.2
1)Objective:   To assess the safet y and tolerability  of the first and second doses of 
VARIVAX™ PE34 process .
2)Objective :  To summarize the VZV antibod y responses after a single dose of 
VARIVAX™ PE34 process and after a single dose of VARIVAX™ ([ADDRESS_205315] ).The VZV immunogenicity  data will be summarized for the 
antibody  response rates , seroconversio n rates andGMTs ,along with the associated 
95% CI  for these parameters. No formal testing will be conducted .
Success for the trialrequires success on the 3hypotheses based on the primary  objectives .
4.0BACKGROUND & RATIONA LE
Background 4.1
Refer to the package insert and Investigator’s Brochure for detailed background information 
onVARIVAX ™.
Pharmaceutical and Therapeutic Background 4.1.[ADDRESS_205316] in latent 
form in the peripheral nerve tissue (ganglia).  Herpes zoster ([HZ] orshingles) may develop 
as a result of the reactivation of latent VZV.
VARIVAX ™is a vaccine indicated for active immunization for the prevention of varicella in 
individuals 12 months of age and older.
Before the introduction of a varicella vaccine (VARI VAX™), an estimated 4 million cases of 
varicella occurred annually  in the [LOCATION_002] [1], resulting in 10,000 hospi[INVESTIGATOR_175977] 100deaths [2] [3].VARIVAX™ was licensed in 1995 after studies demonstrated 
single -dose efficacy  of 70%to 95% against clinical disease and 95% against severe disease 
over a 7-to 10-year follow -up period [4].  Following licensure, vaccine coverage has
increased to an estimated 90% of the pediatric population in the U nited States [5] [6] , thereb y 
reducing varicella incidence by [CONTACT_8622] 91% [5]and varicella -related hospi[INVESTIGATOR_175978] 75% 
to 88% [7] [8] .  During the first 12 years after licensure of VARIVAX ™in the U nited States, 
varicella -related mortality  decreased by 88%, including a 97% reduction in individuals 
younger than 20years of age,and a 96% reduction in individuals younger than 50years of 
age [9]. Recent epi[INVESTIGATOR_175979]™ affords 
long-term protection over [ADDRESS_205317] immunity  to 
unvaccinated individuals in settings where vaccine adoption is widespread [10].  Currently ,  
  04S63N 
  055D6R
Product:  V210 15
Protocol/Amendment No.:  A03 -[ADDRESS_205318]-2017
Confidentialthe Advisory  Committee on Immunization Practices (ACIP) in the [LOCATION_002]
recommend s(as of 2006 )that a 2-dose regime n be administered in childhood [11].
Rationale 4.[ADDRESS_205319] Population 4.2.1
Following the recommendation of a 2-dose varicella vaccination schedule by [CONTACT_63511] ,and 
the approval of other VZV -containing products (ZOSTAVAX™ [zoster vaccine live, [COMPANY_006]] 
and ProQuad™ [measles, mumps, rubella, and varicella virus vaccine live, [COMPANY_006] ]), the 
demand for VZV -containing vaccines has increased.
The VARIVAX PE34 process will extend the availability  of VZ V (Oka/[COMPANY_006]) -containing 
vaccines and is not expected to change the safet y profile or effectiveness of the vaccine.
The purpose of this Phase 3, randomized, double -blind, multicenter, controlled trial is to 
assess the immunogenicity , safet y,and tolerability  of VARIVAX™ PE34 process in 
comparison with VARIVAX™ ([ADDRESS_205320] ).
VARIVAX™ is indicated for active immunization for the prevention of varicella in 
individua ls [ADDRESS_205321] dose of VZV -containing vaccine.
Rationale for Dose Selection/Regimen 4.2.2
Both VARIVAX™ PE34 process and VARIVAX™ ([ADDRESS_205322] ) are 
administered subcutaneously  as a 0.5-mL dose.  The dose of VARIVAX™ PE34 process is 
the same as for VARIVAX™ ([ADDRESS_205323] ) because VARIVAX™ PE34 is 
formulated in such a way to contain the same minimum potency  at the time of release.
All subjects enrolled in this trial will receive 2 doses of trial vaccine administered 
concomitantly  with M-M- R™ II.  This is consistent with the recommended regimens in the 
[LOCATION_002] and European Union (EU).  In the [LOCATION_002], the ACIP recommends a 
2-dose regimen of varicella vaccines.  A minimum interval of 3 months (90 days) is 
recommended between each dose of VZV -containing vaccines when administered to 
children.  In the EU, at least [ADDRESS_205324]:  V210 16
Protocol/Amendment No.:  A03 -[ADDRESS_205325]-2017
ConfidentialRationale for Endpoints 4.2.3
Immunogenicity Endp oints [IP_ADDRESS]
The immunogenicit y endpoints for this trial are consistent with those used in previous 
clinical studies of VARI VAX™. The primary  time point for the assessment of 
immunogenicit y anal yses will be at [ADDRESS_205326] antibody (immunoglobulin G [IgG]) to VZV pre-and postvaccination with 
VZV -containing vaccines.  The gpELISA assay  is the primary  assay used by [CONTACT_175994]; the performance characteristics of this 
assay  have been well established in previous clinical trials.  The response rate for VZV is 
defined as the proportion of subjects with a postvaccination VZV antibody titer ≥5 gpELISA 
units/m L for subjects who were seronegative to VZV (titer <1.25 gpELISA units/mL ) at 
baseline .  An antibod y titer ≥5 gpELISA units/mL correlates with long -term protection [12].
Safety Endpoints [IP_ADDRESS]
Throughout the clinical development program VARI VAX™ has demonstrated anacceptable 
safet y profile inchildren. Moreover, across dose ranges and manufacturing processes, 
aggregate safet y data from the varicella clinical development program demonstrate the 
consistency  of the safety profile of VARIVAX™ , with similar rates of local and systemic 
adverse experiences and temperature data.Additionally , in clinical studies that have
evaluated theconcomitant administration of VAR IVAX™ with M-M-R ™ II, concomitant 
use did not adversel y affect the safet y profile of either vaccine.
In clinical studies using a 2-dose regimen of VZV -containing vaccine in children, the 
incidence of injection -site reactions after vaccination was generally  higher Postvaccination 2 
than Postvaccination 1, although the injection -sitereactions were short in duration and mild 
in intensity  andsize; whereas, significantl y lower incidence sof elevated temperatures and 
noninjection -site varicella -like rashes were observed Postvaccination 2 compared with 
Postvacc ination 1.
As with previous VARIVAX ™studies, the postvaccination safet y follow -up period will be 
42days after each vaccination. The safety  parameters for this trial will include the 
proportion of subjects with the following: 
1)elevated temperatures ≥102.2°F [≥39.0°C] oral equivalent ) up to42 days after each 
trialvaccination ;
2)varicella -like, zoster -like, measles -like, or rubella -like rashes or mumps -like 
symptoms occurring up to 42days after each trial vaccination ;
3)solicited injection -site reacti ons (using the electronic vaccination report card 
[eVRC ]), such as redness, swelling, and pain/tenderness/soreness ,occurring within 
5days after each trialvaccination ; 
  04S63N 
  055D6R
Product:  V210 17
Protocol/Amendment No.:  A03 -[ADDRESS_205327]-2017
Confidential4)all unsolicited injection -site reactions occurring on Days 1through 42 after each trial 
vaccination ;
5)systemic adverse experiences up to 42days after each trialvaccination ;
6)serious adverse experiences throughout the trialduration ;and
7)medically  attended adverse events from Day  133 through Day 271.
Future Biomedical Research [IP_ADDRESS]
The Sponsor will conduct Future Biomedical Research on specimens consented for future 
biomedical research during this clinical trial.  This research may include genetic anal yses 
(DNA), gene expression profiling (RNA), proteomics, metabolomics (serum, plasma) and/or 
the measurement of other analytes, depending on which specimens are consented for future 
biomedical research.
Such research is for biomarker testing to address emergent questions not described elsewhere 
in the protocol (as part of the main trial) and will only be conducted on specimens from 
appropriatel y consented subjects. The objective of collecting /retaining specimens for Future 
Biomedical Research is to explore and identify  biomarkers that inform the scientific 
understanding of diseases and/or their therapeutic treatments. The overarching goal is to use 
such informa tion to develop safer, more effective drugs /vaccines , and/or to ensure that 
subjects receive the correct dose of the correct drug /vaccine at the correct time.  The details 
of this Future Biomedical Research sub-trial are presented in Section 12.2 –Collect ion and 
Management of Specimens for Future Biomedical Research.
Benefit/Risk 4.3
Subjects in this trial are expected to receive the same benefit, as established with 
VARIVAX™ and M-M- R™ II. The change in production process is not expected to affect 
the benefi t/risk ratio.
Additional details regarding specific benefits and risks for subjects participating in this 
clinical trial may be found in the accompany ing VARIVAX™ package insert and 
Investigator’s Brochure , M-M- R™ II package insert , and informed consent documents .
5.0METHODOLOGY
Entry Criteria 5.1
Diagnosis/Condition for Entry into the Trial 5.1.1
Health y children who are between 12and 23months of age(inclusive) will be enrolled in 
this trial. 
  04S63N 
  055D6R
Product:  V210 18
Protocol/Amendment No.:  A03 -[ADDRESS_205328]:
1.Be between [ADDRESS_205329] trial vaccination 
(subject is able to enroll up to 1 day before 24 months of age ).
2.Be in good health based on medical history.
3.Have a negative clinical history  for va ricella, HZ, measles, mumps ,and rubella.
4.Be able to complete all scheduled visits and comply  with the trialprocedures.
5.Have a parent/ legall y acceptable representative who understands the trial 
procedures, alternate treatments available, and risks involved with the trial and 
voluntarily  agree to participate in the trial by [CONTACT_11682] .
6.Have a parent/ legall y acceptable representative who is able toread, understand, 
and complete the eVRC .
7.Have aparent/ legally  acceptable representative who also acknowledges that he or 
she:
a.will attend all scheduled visits
b.will comply with the trial procedures, and
c.will have access to a telephone and be willing to complete the safety 
follow -up phone call .
8.The subject’s parent/ legally  acceptable representative may also provide written 
informed consent/assent for Future Biomedical Research.  However, the subject 
may participate in the main trial without participating inFuture Biomedical 
Research.
Subject Exclusion Criteria 5.1.[ADDRESS_205330]:
*If the subject m eets any of the exclusion criteria marked with an asterisk (*), the Day  1 visit 
may be rescheduled for a time when these exclusion criteria are no longer met; however, 
the subject would onl y be permitted to continue with a delay ed vaccination if the visit can 
be performed within [ADDRESS_205331]:  V210 19
Protocol/Amendment No.:  A03-[ADDRESS_205332]-2017
Confidential2.Has any congenital or acquired immune deficiency , neoplastic disease, or 
depressed immunity , including those resulting from corticosteroid use (see 
Exclusion Criterion #3 and Section 5.5 – Concomitant Medications) or other 
immunosuppressive therapy.
3.Has received 1) systemic immunomodulatory steroids (no more than the 
equivalent of 2 mg/kg total daily  dose of prednisone or >20 mg/day  of prednisone 
or equivalent for subjects weighing >10 kg) for more than 7 consecutive days
within 3months before entering trial, or 2)any dose of systemic 
immunomodulatory  steroids within 7days before entering trial, or 3) is expected 
to require s ystemic immunomodulatory  steroids during the course of the trial.
Exception:   Subjects who require nons ystemic steroids (e.g.,topi[INVESTIGATOR_2855], ophthalmic, 
inhaled) will be eligible for vaccination.
4.Has any blood dyscrasias, leukemia, lymphomas of any type, or other malignant 
neoplasms affecting the bone marrow or l ymphatic sy stems.
5.Has a history  of allergy or anaph ylactic reaction to neomy cin, gelatin, sorbitol, 
egg proteins (egg or egg products), chicken proteins ,or any component of 
VARIVAX™ or M -
M-R™ II , as stated in the package insert s.
6. *Has received salicy lates (e.g.,aspi[INVESTIGATOR_175980] -containing products) within 
14days before vaccination.
7.
*Has had an exposure to varicella, HZ, measles, mumps ,or rubella in the last 
4weeks before trialvaccination involving:
a.Continuous household contact, or
b.Playmate contact (generally  >1 hour of indoor play ),or
c.Hospi[INVESTIGATOR_175981] (in the same 2-to 4-bed room or in adjacent beds in a 
large ward or prolonged face-to-face contact [CONTACT_175995]), or
d. Contact [CONTACT_4490] a newborn whose mother hadanonset of chickenpox within 
≤5days before delivery  or within 48 hours after delivery .
8.*Was vaccinated with a licensed, inactivated (nonlive )vaccine (e.g., i nactivated 
poliovirus [IPV], Diphtheria, Tetanus, and Acellular Pertussis [DTaP], 
Haemophilus influenzae type b [Hib]) within 14days or less 
before any dose of 
the trial vaccines or is expected to be vaccinated during the 42-day safety follow-
up period after each trialvaccination.
9.*Was vaccinated with any licensed live vaccine within ≤
30days before any dose 
of the trial vaccines or is expected to be vaccinated within the 42-day safet y 
follow -up period after each trialvaccination. 
  04S63N 
  055D6R
Product:  V210 20
Protocol/Amendment No.:  A03 -[ADDRESS_205333]-2017
Confidential10.*Has had a recent (within 72 hours) history  of febrile illness (102.2°F [39.0C] 
oral equivalent) before the trial vaccination. Temperatu re may be converted to 
oral equivalent by [CONTACT_1583] 1.0°F to axillary  temperatures and subtracting 1.0°F 
from rectal temperatures .
11.Has received immun oglobulin, a blood transfusion ,or blood -derived products 
(does not include autologous blood/blood products) within 5 months before 
vaccination or plans to receive these products while enrolled in this trial.
12.Has a history  of seizure disorder, including single febrile seizure.
13.Has a history  of thrombocy topenia.
14.Was born to a human immunodeficiency  virus (HIV)-infected mother.
15.Has a d iagnosis of active untreated tuberculosis.
16.Is currentl y participating in (30days or less before enrollment) or scheduled to 
participate in any other clinical trial other than a surveillance trial during the 
planned trial period for this trial.
17.Has any other underly ing medical condition that, in the opi[INVESTIGATOR_1070], may  interfere wi th the evaluation of trialobjectives.
18.Is or has an immediate family  member (e.g., spouse, parent/legal guardian, sibling  
or child) who is investigational site or Sponsor staff directl y involved with this 
trial.
Subject Deferment Criteria ( Before Vaccination 2) [IP_ADDRESS]
These subject deferment criteria must be reviewed for each subject before Vaccination [ADDRESS_205334], and/or that Vaccination [ADDRESS_205335]:
19.Has had exposure to varicella or HZ Postv accinati on 1 (defer Vaccination 2 until 
4weeks after the exposure):
a.Continuous household contact, or
b.Playmate contact (generally  >1 hour of indoor play ), or
c.Hospi[INVESTIGATOR_175981] (in same 2-to 4-bedroom or adjacent beds in a large ward or 
prolonged face -to-face cont act with an infectious staff member or patient ), or
d.Contact [CONTACT_4490] a newborn whose mother had onset of chickenpox within 
≤5days before delivery  or within 48 hours after delivery .
20.Has had exposure to measles, mumps, or rubella since Vaccination 1 (defer 
Vaccination 2 until 4 weeks after exposure). 
  04S63N 
  055D6R
Product:  V210 21
Protocol/Amendment No.:  A03 -[ADDRESS_205336]-2017
Confidential21.Has had recent (within 72 hours) history  of febrile illness ( ≥102.2°F [39.0°C] oral 
equivalent) before the trial vaccination (defer Vaccination 2until >72 hours after 
resolution of febrile illness). Temperatur e may be converted to oral equivalent by 
[CONTACT_1583] 1.0°F to axillary  temperatures and subtracting 1.0°F from rectal 
temperatures.
22.Has received any dose of systemic immunomodulatory  steroids within 7days 
before Vaccination 2 (defer Vaccination 2until a minim um of 7 days after 
systemic immunomodulatory  steroids ).
23.Has had any licensed inactivated vaccine administered since Vaccination 1 (defer 
Vaccination 2 until a minimum of 15 days after non trialvaccination[s] ).
24.Has had any licensed live vaccine administered since Vaccination 1 (defer 
Vaccination 2 until a minimum of 31 days after non trialvaccination[s] ).
25.Has had receipt of salicy lates (e.g., aspi[INVESTIGATOR_175980] -containing products) 
since Vaccination 1 (defer Vaccination 2 until 14 day s after taking medication).
26.Has had any medical condition that, in the opi[INVESTIGATOR_871], may 
interfere with the evaluation of the trial objectives. (The amount of time 
Vaccination 2 is deferred will be determined b y the investigator.)
Criteria for Excluding Subjects from Receiving Vaccination 2 [IP_ADDRESS]
These subject exclusion criteria must be reviewed for each subject before Vaccination [ADDRESS_205337]:
27.Has had any immun oglobulin, nonautologous blood ,or blood products 
administered Postv accination 1.
28.Has had any nontrial measles -, mumps -, rubella -, or VZV -containing vaccine 
administered Postv accination 1.
29.Has received systemic immunomodulatory  steroids (no more than the equivalent 
of >2mg/kg total daily dose of prednisone or equivalent or >20mg/day  of 
prednisone or equivalent for subjects weighing >10 kg) for more than 
7consecutive day sPostv accination 1.
30.Has any blood dyscrasias, leukemia, lymphomas of any type, or other malignant 
neoplasms affecting the bone marrow or lymphatic systems diagnosed 
Postv accination 1.
31.Has had any acquired or congenital immunodeficiency  or active tuberculosis 
diagnosed Postv accination 1.
32.Has had the occurrence of varicella infection Postv accination 1.
33.Has had a vaccine -related allergic or anaphy lactoid reaction reported 
Postv accination 1. 
  04S63N 
  055D6R
Product:  V210 22
Protocol/Amendment No.:  A03 -[ADDRESS_205338]-2017
Confidential34.Has enrolled in any other clinical trial other than a surveillance trial
Postv accination 1.
35.Has had a seizure, including a febrile seizure, Postv accination 1.
36.Has had thrombocy topenia Postv accination 1.
Trial Vaccination(s) 5.2
The v accine s to be used i n this trial are outlined below in Table 1.
Table 1 Trial Vaccination s
Vaccine Dose/Potency Dose 
FrequencyRoute of 
AdministrationVaccination 
RegimenUse 
VARIVAX™ PE34 
process (Group 1)0.5 mL after 
reconstitution2 doses ; 
3months 
betw een 
each doseSubcutaneous
injectionVisit 1 (Day 1) and 
Visit 3 (Week 13 
[Day s 91-105])Investigational
VARIVAX™ ([ADDRESS_205339]) 
(Group 2)0.5 mL after 
reconstitution2 doses ; 
3months 
betw een 
each doseSubcutaneous
injectionVisit 1 (Day 1) and 
Visit 3 (Week 13 
[Day s 91-105])Standard of care
M-M- R™ II
(Groups 1 and 2)0.5 mL after 
reconstitution2 doses ; 
3months 
betw een 
each doseSubcutaneous
injectionVisit 1 (Day 1) and 
Visit 3 (Week 13 
[Day s 91-105])Standard of care
Vials of vaccine will be labeled with component identification numbers (CIDs). Care should 
be taken to ensure that each subject receives the appropriate clinical materials labeled with 
their specific CID.
Trial vaccinations are given on the day  of randomization or as close as possible to the date on
which the subject is allocated/assigned. All supplies indicated inTable 1above will be 
provided centrally  by [CONTACT_1034].
The investigator shall take responsibility  for and shall take all steps to maintain appropriate 
records and ensure appropriate suppl y, storage , handling, distribution and usage of trial 
treatments in accordance with the protocol and an y applicable laws and regulations.
Dose Selection 5.2.1
Dose Selection (Preparation) [IP_ADDRESS]
The rationale for selection of doses to be used in this trial is provided in Section 4.0 –
Background & Rationale.  There are no specific calculations or evaluations required to be 
performed in order to administer the proper dose to each subject. 
  04S63N 
  055D6R
Product:  V210 23
Protocol/Amendment No.:  A03 -[ADDRESS_205340]-2017
ConfidentialTiming of Dose Administration 5.2.2
Subjects will be randomized to 1 of 2 vaccination groups to receive either two 0.5-mL 
subcutaneous doses of VARI VAX™ PE34 process (Group 1) or two 0.5-mL subcutaneous 
doses of VARIVAX™ ([ADDRESS_205341] )(Group 2) approximately  3 months apart.  
Dose 1 will be administered at Visit 1 on Day 1 of  the trial, and Dose 2 will be administered 
at Visit 3(Week 13 [Days 91-105]). Each dose of VARIVAX™ PE34 process and 
VARIVAX™ ( [ADDRESS_205342] )will be administered concomitantly  with 
M-M- R™ II.
Trial Blinding 5.2.3
A double -blinding technique with in-house blinding will be used.  VARI VAX™ PE34
process and VARIVAX™ ([ADDRESS_205343] ) will be packaged identically  so that 
the blind is maintained. The subject, the investigator and Sponsor personnel or delegate(s) 
who are involved in the vaccine administration or clinical evaluation of the subjects are 
unaware of the group assignments.
See Section [IP_ADDRESS], Blinding/Unblinding, for a description of the method of unblinding a 
subject during the trial, should such action be warranted.
Randomizat ionor Vaccine Allocation 5.3
Vaccine randomization will occur centrally using an interactive voice response 
system /integrated web response system (IVRS/IWRS).  There are 2 vaccination groups .  
Subjects will be assigned randomly  in a 1:1 ratio to VARIVAX™ PE34 process (Group 1) or 
VARIVAX™ ( [ADDRESS_205344] )(Group 2), respectively .
Stratification 5.4
No stratification based on age, sex or other characteristics will be used in this trial.
Concomitant Medications /Vaccinations (Allowed andProhibited) 5.5
Medications or vaccinations specifically  prohibited in the exclusion criteria are not allowed 
during the ongoing trial.  If there is a clinical indication for any medication or vaccination 
specificall y prohibited during the trial, discontinuation from trial therapy  or vaccination may 
be required.  The investigator should discuss any questions regarding this with the Sponsor 
Clinical Director.  The final decision on any supportive therap y or vaccin ation rests with the 
investigator and/or the subject's primary  physician.  However, the decision to continue the 
subject on trial therapy or vaccination schedule requires the mutual agreement of the 
investigator, the Sponsor and the subject ’s legally  accep table representative .
All medications administered from [ADDRESS_205345]:  V210 24
Protocol/Amendment No.:  A03-[ADDRESS_205346] received salicy lates (e.g., aspi[INVESTIGATOR_175980]- containing 
products) during the 14days before Vaccination 1, and should not receive these products 
until after 42days after Vaccination 2, because the use of salicy lates in children with 
varicella has been associated with Reye syndrome. Subjects must not have received any 
immun oglobulin, a blood transfusion ,or blood -derived products (does not include autologous 
blood/blood products) for at least 5months (150 days) before vaccination and should not 
receive these products while enrolled in this trial, unless there is a medical necessit y 
warranting their use.
Use of immunosuppressive therapi[INVESTIGATOR_175982], with the following exceptions :
1. Use of topi[INVESTIGATOR_2855], ophthalmic, and inhaled steroids ispermitted.
2.Use of s ystemic immunomodulatory steroids must meet the following criteria:
Subjects should not receive any dose of systemic immunomodulatory steroids within
7days before or after each vaccination .
Subjects should not receive systemic immunomodulatory  steroids (no more than the 
equivalent of 2 mg/kg total daily  dose of prednisone or equivalent or >20mg/day  of 
prednisone or equivalent for subjects weighing >10 kg) for more than [ADDRESS_205347] otherwise develops an immunosuppressive condition in this interval, 
then the 
second dose of trialvaccines should be discontinued.
It is preferable that other vaccines routinely  administered to children who are between
12months to 23 m onths of age be given outside of the trial period so as not to confound the 
results from this trial.  These vaccines will not be provided by [CONTACT_175996].  If necessary , enrollment in the trial can be deferred if a medically  important 
vaccine needs to be administered ; however, the subject would only be permitted to continue 
with a delay ed vaccination if the visit can be performed within the allowed window .  A full 
15days must elapse between the receipt of inactivated nontrial vaccines and enrollment into 
the trial. A full [ADDRESS_205348] elapse between the receipt of live nontrial vaccines (e.g., 
yellow fever) and enrollment into the trial.
If medicall y necessary , both licensed inactivated and live nontrial vaccines may be 
administered in the interval between Visit 2 and Visit 3.  As specified in Section 
5.1.3, a 
minimum of 43 days should elapse between Visit 1 (when the first dose of trial vaccine is 
administered) and receipt of the inactivated or live non trialvaccine.  In addition:
If a licensed, inactivated (nonlive )vaccine (e.g., IPV, DTaP, Hib) is given between 
Visits [ADDRESS_205349] elapsed.
If a licensed live vaccine is given between Visits [ADDRESS_205350]:  V210 25
Protocol/Amendment No.:  A03 -[ADDRESS_205351]-2017
ConfidentialAfter the successful completion of trial procedures at Visit 4 (Week 19 [Day s 133-147 
Postvaccination 1]), both inactivated and live non trialvaccines may  be administered.
Rescue Medications & Supportive Care 5.6
No rescue or supportive medications are specified to be used in this trial.
See Section [IP_ADDRESS].3 , General Precautions for Administration, regarding administration of
epi[INVESTIGATOR_175983].
Diet/Activity/Other Considerations 5.[ADDRESS_205352] Withdrawal/Discontinuation Criteria 5.[ADDRESS_205353]’s last scheduled follow -up, even if the 
subject has discontinued vaccination .  Therefore, all subjects who discontinue trial 
vaccination prior to completion of the vaccination period will still continue to participate in 
the trial as specified in Section 6.0 (Trial Flow Chart) and Section [IP_ADDRESS] (Discontinued 
Subjects Continuing to be Monitored in the Trial )unless consent is withdrawn .For subjects 
who will not receive Vaccination 2, all tasks except vaccination and eVRC should be 
completed.
Subjects may discontinue vaccination at any time for any reason or be dropped from 
vaccination at the discretion of the investigator shou ld any untoward effect occur.  In 
addition, a subject may be discontinued from vaccination by [CONTACT_175997], the trial plan is violated, or for administrative and/or other 
safet y reasons.  Specific details regarding procedures to be performed at vaccination
discontinuation are provided in Section 7.1.4 –Other Procedures.
A subject must be discontinued from vaccination but continue to be monitored in the trial for 
any of the following reasons :
○The subject or subject’s legall y acceptable representative requests to discontinue 
vaccination .
oThe subject has a medical condition or personal circumstance that, in the opi[INVESTIGATOR_120484]/or Sponsor, places the subject at unnecessary  risk throug h 
continued participation in the trial or does not allow the subject to adhere to the 
requirements of the protocol.
oThe subject meets an y of the criteria in Section 5.1.[ADDRESS_205354]:  V210 26
Protocol/Amendment No.:  A03 -[ADDRESS_205355]-2017
ConfidentialFor subjects who are discontinued from vaccination but continue to be monitored in the trial, 
all visits and procedures, as outlined in the trial flowchart, except vaccination and eVRC 
should be completed.
Discontinuation from vaccination is “permanent.” Once a subject is discontinued, he/she 
shall not be allowed to restart vaccination .
Withdrawal from the Trial 5.8.[ADDRESS_205356] ’s legally  acceptable representative 
withdraws consent from the trial.
If a subject withdraws from the trial, they will no longer receive vaccination or be followed 
at scheduled protocol visits.
Specific details regarding procedures to be performed at the time of withdrawal from the trial 
including the procedures to be performed should a subject repeatedl y fail to return for 
scheduled visits and/or if the study  site is unable to contact [CONTACT_423], as well as specific 
details regarding withdrawal from Future Biomedical Research are outline d in Section 7.1.4 
–Other Procedures.
Subject Replacement Strategy 5.[ADDRESS_205357] to follow -up (i.e. the subject is unable to be contact[CONTACT_103200]).   For purposes of analysis and reporting, the overall study  ends when the 
Sponsor receives the last serology assay result.
Clinical Criteria for Early Trial Termination 5.11
There are no pre -specified criteria for terminating the trial earl y. 
  04S63N 
  055D6R
Produc t:  V210 27
Protocol/Amendment No.: A03-[ADDRESS_205358]-2017
Confidential6.0TRIAL FLOW CHART
Visit Number: 1 2 3 4 5
Visit Title:Randomization/
Vaccination 1Vaccination 1 
Follow -upaVaccination 2bVaccination 2 
Follow -upa,cPhone Callc
Trial Timing: Week 1 Week 6 Week 13 Week 19 Month 9
Trial Days: Day [ADDRESS_205359] X
Review inclusion /exclusion criteria X
Review deferment /exclusion criteria (before Vaccination 2) X
Review medical h istory X
Review concomitant medication and nontrialvaccines X X X X
Assign treatment allocation/ randomization using IVRS /IWRS X X
Laboratory Procedures/Assessments
Obtain buccal swabs(DNA) for Future Biomedical ResearchdX
Obtain blood sample for immunogenicity testingeX X
Clinical Procedures/Assessments
Take temperature (oral or equivalent)fX X
Administer VARIVAX™ (left arm [or left anterolateral thigh] )f
Group 1: VARIVAX™ PE34 process
Group 2: VARIVAX™ ([ADDRESS_205360])X X
Administer M -M-R™ II (right arm [or right anterolateral thigh] )fX X
Observe subject for anaphylaxis or other allergic reaction (at least 30 minutes) X X
Distribute eVRC /review instructions with subject/legally acceptable representativegX X
Review eVRC reports with legally acceptable representativehX X
Educate subject /legally acceptable representative on serious adverse event s definition 
and reportingX X X X
Review adverse events and s erious adverse eventsiX X X
Collect eVRC device X
Active assessment (using scripted safety questions) for occurrence of possible serious 
adverse events and medically attended adverse eventsX
a. Visit [ADDRESS_205361] the DNA sample.   
  04S63N 
  055D6R
Produc t:  V210 28
Protocol/Amendment No.: A03-[ADDRESS_205362]-2017
ConfidentialVisit Number: 1 2 3 4 5
Visit Title:Randomization/
Vaccination 1Vaccination 1 
Follow -upaVaccination 2bVaccination 2 
Follow -upa,cPhone Callc
Trial Timing: Week 1 Week 6 Week 13 Week 19 Month 9
Trial Days: Day 1 Days43-57 Days91-105 Days133-147 Days271-285
e. A 3-mL blood sample will be taken on Day 1, immediately before vaccination with VARIVAX™ and at Week 6 ( 43-57 days after Day 1 vaccination with VARIVAX™. The 
Visit 1 (Day 1) immunogenicity 
blood sample is mandatory for enrollment. Leftover main trial serum will be stored for future biomedical research if the parent/legally 
acceptable representative consent s to future biomedical research .
f. Before vaccination with trial vaccine, review all eligibility criteria, including subject’s temperature.  If the subject has a fever (defined as an oral temperature of 102.2°F 
(39.0C) or equivalent, the subject should not receive trial vaccine and the vaccination visit should be rescheduled until >[ADDRESS_205363]’s axillary temperature is ≥98.6°F (37.0°C), the parent/legally acceptable representative will be requested to further measure and reco rd the subject’s rectal temperature 
in the eVRC. Parents/legally acceptable representatives should only record axillary temperatures and rectal temperatures as indicated. Oral temperatures and otic temperatures 
should not be recorded by [CONTACT_3654]/legally acc eptable representatives .
g. The eVRC device is dispensed at Visit
1.  Only instructions are reviewed at Visit 3.
h. The eVRC (Section [IP_ADDRESS]) is required to be completed for a full [ADDRESS_205364] or parent/legally acceptable representative must be reminded to return with the eVRC device at Vi sit 4.
i. The development of varicella -like, HZ-like, measles -like and rubella -like rashes and mumps -like symptoms through [ADDRESS_205365]’s parent/legally acceptable representative will be instructed to contact [CONTACT_175998] a varicella-or HZ-like rash develops.  Subjects are required 
to be seen at the clinic within [ADDRESS_205366]:   V210 29
Protocol/Amendment No.: A03-[ADDRESS_205367]-2017
Confidential7.0TRIAL PROCEDURES
Trial Procedures 7.1
The Trial Flow Chart -Section 6.0summarizes the trial procedures to be performed at each 
visit.  Individual trial procedures are described in detail below.  It may be necessary  to 
perform these procedures at unscheduled time points if deemed clinically necessary  by [CONTACT_1275].
Furthermore, additional evaluations/testing may  be deemed necessary  by [CONTACT_26357] . In some cases, such evaluation/testing 
may be potentially  sensitive in nature (e.g., HIV, Hepatitis C, etc.), and thus local regulations 
may require that additional informed consent be obtained from the subject ’s legally 
acceptable representative .  In these cases, such evaluations/testing will be performed in 
accordance with those regulations.
Administrative Proce dures 7.1.1
Informed Consent [IP_ADDRESS]
The investigator or qualified designee must obtain documented consent from each potential 
subject’s legally  acceptable representative prior to participating in a clinical trial or Future 
Biomedical Research .If there are changes to the subject’s status during the trial (e.g.,health 
or age of majority  requirements ), the investigator or qualified designee must ensure the 
appropriate consent is in place. 
[IP_ADDRESS].[ADDRESS_205368]’s legally  acceptable representative’s dated 
signature [INVESTIGATOR_2394] a consent form along with the dated signature [CONTACT_75411]. 
A copy  of the signed and dated consent form should be given to the subject ’s legally 
acceptable representative before that subject’s participation in the trial.
The initial informed consent form, any subsequent revised written informed consent form 
and any written information provided to the subject ’s legall y accept able representative must 
receive the IRB/ERC’s approval/favorable opi[INVESTIGATOR_19349].  The subject ’slegall y 
acceptable representative should be informed in a timely  manner if new information becomes 
available that may be relevant to willingness forthe subject to continue participation in the 
trial.  The communication of this information will be provided and documented via a revised 
consent form or addendum to the original consent form that captures the subject’s legall y 
acceptable representative’s dated signature.
Specifics about a trial and the trial population will be added to the consent form template at 
the protocol level.   
  04S63N 
  055D6R
Product:   V210 30
Protocol/Amendment No.: A03-[ADDRESS_205369]-2017
ConfidentialThe informed consent will adhere to IRB/IEC requirements, applicable laws and regulations 
and Sponsor requirements.
[IP_ADDRESS].[ADDRESS_205370] ’s legally acceptable representative , answer all of his/her questions, and obtain 
written informed consent before performing any procedure related to the Future Biomedical 
Research sub-trial.  A  c opy of the informed consent will be given to the subject ’s legall y 
acceptable representative .
Inclusion/Exclusion Criteria [IP_ADDRESS]
All inclusion and exc lusion criteria will be reviewed by  [CONTACT_26358].
Subject Identification Card [IP_ADDRESS]
The legally  acceptable representative for each subject will be given a Subject Identification 
Card identify ing the subject asaparticipant in a research trial. The card will contain trial site 
contact [CONTACT_3031] (including direct telephone numbers) to be utilized in the event of an 
emergency . The investigator or qualified designee will provide the legal ly acceptable 
representative for each subject with thea Subject Identification Card immediately  after 
written informed consent is provided .At the time of treatment allocation/randomization, site 
personnel will add the treatment/randomization number to th e Subject Identification Card.
The subject identification card also contains contact [CONTACT_75345] a health care provider can obtain information about trial 
medication/vaccination in emergency  situations where th e investigator is not available.
Medical History [IP_ADDRESS]
The eligibility  of a subject will be assessed ,and a medical history  will be obtained to ensure 
that the subject satisfies the inclusion and exclusion criteria of the trial.  No physical 
exam ination is required for entry  into the trial.
Prior and Concomitant Medications Review [IP_ADDRESS]
[IP_ADDRESS].[ADDRESS_205371]:   V210 31
Protocol/Amendment No.: A03-[ADDRESS_205372]-2017
Confidential7.[IP_ADDRESS] Concomitant Medications
The investigator or qualified designee will record medication, if any, taken by [CONTACT_175999] l.Prohibited concomitant medications are listed in Section 5.5.
Assignment of Screening Number [IP_ADDRESS]
All consented subjects will be given a unique screening number that will be used to identify 
the subject for all procedures that occur prior to randomization or treatment allocation .  Each 
subject will be assigned only one screening number.  Screening numbers must not be re -used 
for different subjects.
Any subject who is screened multiple times will retain the original screening number 
assigned at the initial screening visit.
Assignment of Treatment/ Randomization Number [IP_ADDRESS]
All eligible subjects will be randoml y allocated and will receive a treatment/ randomization 
number.  The treatment/ randomization number identifies the subject for all procedures 
occurring after randomization.  Once a treatment/ randomization number is assigned to a 
subject, it can never be re -assigned to another subject.
A single subject cannot be assigned more than 1 treatment/ randomization number.
Trial Compliance (Medication/Diet/Activity) [IP_ADDRESS]
Trial vaccine will be administered by [CONTACT_27404].  No special 
restrictions on diet or activity  appl y.
Distribution of Electronic Vaccination Report Card (eVRC) [IP_ADDRESS]
The eVRC for this trial was developed to be provided electronically  via a hand -held device.  
This item was structured as recommended in the final Food and Drug Administration (FDA) 
Patient Reported Outcome (PRO) Guidance.  The investigator or delegate will train the 
subject/ parent or legally acceptable representative in the use of the eVRC device before
dispensing it to the subject/ parent or legall y acceptable representative at Visit [ADDRESS_205373]/ parent or legally  
acceptable representative at Visit 3.  At Visit 3, the subject /parent or legall y acceptable 
representative must be reminded to return with the eVRC device at Visit 4. Specific 
injection -site reactions will be solicited from Day 1 through Day 5 after vaccination with the 
trial vaccine (VARIVAX™ PE34 or VARI VAX™ [ADDRESS_205374]) and M -M-R™ 
II.  Daily temperatures will be recorded on theeVRC from Day [ADDRESS_205375]’s axillary  temperature is ≥98.6°F (37.0°C), the parent/ legall y 
acceptable representative will be requested to further measure and record the subject’s rectal 
temperature in the eVRC.  The investigator or delegate will review the data captured on the 
eVRC with the subject at Visit [ADDRESS_205376]:   V210 32
Protocol/Amendment No.: A03-[ADDRESS_205377]-2017
ConfidentialClinical Procedures/Assessments 7.1.2
Vaccine Administration [IP_ADDRESS]
[IP_ADDRESS].[ADDRESS_205378] all 
of the diluent in the syringe into the vial of lyophilized vaccine and gently  swirl to mix 
thoroughl y. Withdraw and administer the entire contents (~0.5 mL ) of the vial.
CAUTION: 
•Sterile syringes should be free of preservatives, antiseptics, and detergents asthese 
substances may  inactivate the vaccine virus.
•Protect the vaccine from light at all times since such exposure may inactivate the 
vaccine virus. It is recommended that the vaccine be administered immediately  after 
reconstitution to minimize loss of p otency .
•Do not freeze reconstituted vaccine .
[IP_ADDRESS].2 Administration of Trial Vaccines
VARIVAX™ should be administered subcutaneously  in the outer aspect of the upper left 
arm (deltoid) or left anterolateral thigh . All vaccinations and location of injection should
be recorded on the appropriate eCRF . A 25-gauge, 5/8" needle is recommended.   Subjects 
should be observed for anaphy laxis or other reactions for at least 30 minutes after
vaccination.
M-M- R™ II should be administered subcutaneously  in the outer aspect ofthe upper right 
arm (deltoid) or right anterolateral thigh . All vaccinations and location of injection 
should be recorded on the appropriate eCRF . A 25-gauge, 5/8" needle is recommended.   
Subjects should be observed for anaphy laxis or other reactions for at least 30minutes after
vaccination.
Details of the vaccination should be documented , including the time the vaccine vial is 
removed from the refrigerator, the time of reconstitution, the time of administration of the 
vaccine, the site and route of administration, and the dose volume administered. If not used 
within [ADDRESS_205379]:   V210 33
Protocol/Amendment No.: A03-[ADDRESS_205380]-2017
Confidential7.[IP_ADDRESS] General Precaution for Administration of Vaccine
Adequate treatment provision, including epi[INVESTIGATOR_238], should be available for immediate use 
should an anaphy lactic reaction occur. Subjects should be observed for anaphylaxis or other 
reactions for at least [ADDRESS_205381] to prevent transmission of infectious agents from 
one person to another. Needles should not be recapped. Safe disposal procedures should be 
followed.
[IP_ADDRESS].4 Temperature Procedures
The parent/ legall y acceptable representative for each subject will be instructed to measure 
and record 
in the eVRC the subject’s axillary  temperature [ADDRESS_205382]’s axillary  temperature is ≥98.6°F (37.0°C), the parent/ legally  acceptable 
represe ntative will be requested to further measure and record the subject’s rectal 
temperature in the eVRC.  Trial personnel should advise the parent/legall y acceptable 
representative on the proper manner in which to measure axillary  and rectal temperatures to 
ensure that accurate measurements are obtained.  The parents/legally  acceptable 
representative should not record oral or otic temperatures.
[IP_ADDRESS].5 Clinical Follow- up
Subjects will be followed for adverse event s through 42 day s after each vaccination. Specific 
injection- site reactions will be solicited from Day 1 through Day 5 after vaccination with the 
trial vaccine (VARIVAX™ PE34 or VARI VAX™ [ADDRESS_205383] ) and M -M-R™ 
II. Daily temperatures will be recorded on an e VRC from Day 1through Day 42 after
vaccination. Regardless of severit y or causality , all unsolicited injection -site reactions; and 
all systemic adverse events, including varicella -
,zoster -, measles -, rubella -like rashes and 
mumps- like symptoms ,will be recorded on an e VRC for Day [ADDRESS_205384] dose of trial vaccine through Day 180 after the second dose of trial vaccine.   Medicall y 
attended adverse events will be repor ted from Day 133 through Day 271.  During the phone 
call at Day 271 (Day  180 Postvaccination 2), a scripted questionnaire will be used to 
determine if any serious adverse event s or medically  attended adverse events have occurred 
for each subject since completing the 42- day safety  follow -up period Postvaccination 2.
The parent/ legally  acceptable representative of each subject will record the safety  data on the 
eVRC and return the eVRC to the trial siteat Visit 4. Trial personnel will review the eVRC 
fo
r completeness, accuracy ,and clarit y. All information will be accurately  recorded on the 
appropriate eCRFs . 
  04S63N 
  055D6R
Product:   V210 34
Protocol/Amendment No.: A03-[ADDRESS_205385]-2017
ConfidentialLaboratory Procedures/Assessments 7.1.3
Details regarding specific laboratory  procedures/assessments to be performed in this trial are 
provided below. The total amount of blood/tissue to be drawn/collected over the course of 
the trial (from pretrial to post-trial visits), including approximate blood/tissue volumes 
drawn/collected b y visit and by [CONTACT_176000] ,can be found in Section 12.3.
Labo ratory Immunogenicity Evaluations [IP_ADDRESS]
[IP_ADDRESS].[ADDRESS_205386] before vaccination at Visit 1 
(Day  1) and at Visit 2 (Day  43 [+14days] Postvaccination 1). For all subjects at Visit 1 
(Day 1), it is mandatory  to collect a blood sample before a subject is randomized.  Subjects 
must not be randomized into the trial if a blood sample cannot be obtained. Serum should be 
collected, processed, and shipped according to the instruction s provided in the laboratory 
manual. All serum specimens will be sent to [COMPANY_003] Vaccines and Biologics, LLC, Richmond , 
VA, [LOCATION_003], on dry  ice.
[IP_ADDRESS].2 Detection of IgG Antibody to VZV (gpELISA)
The purpose of the gpELISA is to detect IgG antibody  to VZV before and after vaccination 
with VZV -containing vaccine(s). This is the primary  assay used to evaluate the serological 
response to VZV -containing vaccine(s). This method detects antibodies to VZV 
glycoprotein (gp), which has been purified from MRC -5 cells infected with the KMcC strain 
of VZV by [CONTACT_115576] -affinity chromatography . The reactivity  of the sera to the gp antigens from 
uninfected MRC -5 cells (denoted as tissue culture control [TCC] wells]) is subtracted from 
the reactivity  of the sera to the gp antigens purifie d from VZV -infected MRC -5 cells. The 
assay  and the purification of the VZV gp from VZV-infected cells are described [13] [14] 
[15]. Serum sample titers as determined by [CONTACT_176001] y titers [16].
For the gpELISA, VZV gp or TCC antigen is adsorbed to polystyrene microtiter wells and 
used as the solid phase antigen. Experimental, control, and standard curve sera are incubated 
in VZV gp-coated and TCC -coated wells (2 wells for each antigen). For each serum sample, 
a delta optical densit y (DOD) is calculated as the difference between the average optical 
density  (OD)of the 2VZV antigen wells and the average OD of the [ADDRESS_205387] curve. Results for 
the assay  are reported as concentration of antibody  in gpELISA units/mL .
The negative control used for this assay  is an individu al human serum at a dilution of 1:50, 
found to be negative for anti-VZV. The high-positive control is a VZV antibody -positive 
serum, diluted 1:500, which gives a response in the assay  at the upper end of the standard 
curve. The low-positive control is a VZV antibody -positive serum diluted 1:50, which gives 
a response in the assay  at the lower end of the standard curve. A VZV antibody- positive 
individual human serum was used to generate a standard curve. 
  04S63N 
  055D6R
Product:   V210 35
Protocol/Amendment No.: A03-[ADDRESS_205388]-2017
ConfidentialFuture Biomedical Research Sample s [IP_ADDRESS]
The following specimens are to be obtained as part of Future Biomedical Research:
DNA for future research
Leftover main trialserum from immunogenicit y testing stored for future research
Other Procedures 7.1.4
Withdrawal/Discontinuation [IP_ADDRESS]
Subjects who discontinue vaccination prior to completion of the vaccination regimen should 
be encouraged to continue to be followed for all remaining study visits.
When a subject discontinues/withdraws from participation in the trial , all applicable activities 
scheduled for the final trial visit should be performed at the time of discontinuation.  Any 
adverse events which are present at the time of discontinuation/withdrawal should be 
followed in accordance with the safety  requirements outlined in Section 7.2 -Assessing and 
Recording Advers e Events.
[IP_ADDRESS].[ADDRESS_205389] ’s consent for Future Biomedical Research may be withdrawn by [CONTACT_423]’s 
legally  acceptable representative .  A subject ’s consent may be withdraw nat any time by 
[CONTACT_176002].  If medical records for the main trial 
are still available, the investigator will contact [CONTACT_75355] 
([EMAIL_1250]).  Subsequently , the subject's consent for Future 
Biomedi cal Research will be withdrawn.  A  l etter will be sent from the Sponsor to the 
investigator confirming the withdrawal. It is the responsibility  of the investigator to inform 
the subject of completion of withdrawal.  Any analyses in progress at the time of request for 
withdrawal or alread y performed prior to the request being received by [CONTACT_75356].  No new analyses 
would be generated after the request is received.
In the event that the medical records for the main trial are no longer available (e.g., if the 
investigator is no longer required by [CONTACT_75357]) or 
the specimens have been completely  anony mized, there will no longer be a link between the 
subject’s personal information and their specimens.  In this situation, the request for 
specimen withdrawal cannot be processed. 
  04S63N 
  055D6R
Product:   V210 36
Protocol/Amendment No.: A03-[ADDRESS_205390]-2017
Confidential7.[IP_ADDRESS] Lost to Follow -up
If a subject fails to return to the clinic for a required trial visit and/or if the site is unable to 
contact [CONTACT_7071] /legally acceptable representative , the following procedures are to be 
performed:
The site must attempt to contact [CONTACT_7071]/legally acceptable representative and 
reschedule the missed visit.  If the parent/legally  acceptable representative is 
contact[INVESTIGATOR_530], the parent/legally  acceptable representative should be counseled on the 
importance of maintaining the protocol -specified visit schedule.
The investigator or designee must make every  effort to regain contact [CONTACT_176003]/legall y acceptable representative at each missed visit (e.g.,phone calls 
and/or a certified letter to the last known mailing address of the parent/legall y 
acceptable representative or local equivalent methods). These contact [CONTACT_131994]’s medical record.
Note:  A subject is not considered lost to follow up until the last scheduled visit 
for the individual subject.  The amount of missing data for the subject will be 
managed via the pre -specified data handling and analy sis guideline s.
Subject Blinding/Unblinding [IP_ADDRESS]
When the investigator or delegate needs to identify  the drug used by  a subject and the dosage 
administered in case of emergency  e.g., the occurrence of serious adverse events , he/she will 
contact [CONTACT_75362] a request for emergency  
unblinding.  As requested by [CONTACT_176004]/her promptly  and report unblinding to the Sponsor .  
Prior to contact[CONTACT_90074] a subject’s 
treatment assignment, the investigator or delegate must enter the intensity  of the adverse 
events observed, the relation to study  drug, the reason thereof, etc., in the medical char t etc.
Subjects whose treatment assignment has been unblinded by [CONTACT_093]/delegate and/or 
non-study  treating phy sician must be discontinued from study  drug, but should continue to be 
monitored in the trial.
Additionally , the investigator must go into the IVRS system and perform the unblind in the 
IVRS system to update drug disposition.  In the event that the emergency  unblinding call 
center is not available for a given site in this trial, IVRS/I WRS should be used for emergency 
unblinding in the event that this is required for subject safet y.
Treatment/Vaccine identification information is to be unmasked ONLY if necessary  for the 
welfare of the subject.  Every effort should be made not to unblind the subject unless 
necessary . 
In the event that unblinding has occurred, the circumstances around the unblinding (e.g., 
date, reason and person performing the unblinding ) must be documented promptly , and the 
Sponsor Clinical Director notified as soon as possible. Only  the principal investigat[INVESTIGATOR_1660] [INVESTIGATOR_1660]  
  04S63N 
  055D6R
Product:   V210 37
Protocol/Amendment No.: A03-[ADDRESS_205391]’s code should be unblinded. Other t rial site personnel and 
Sponsor personnel directly associated with the conduct of the trial should not be unblinded.
At the end of the trial, random code/d isclosure envelopes or lists and unblinding logs are to 
be returned to the Sponsor or designee.
Calibration of Critical Equipment [IP_ADDRESS]
The investigator or qualified designee has the responsibility  to ensure that any critical device
or instrument used for a clinical evaluation/test during a clinical trial that provides important 
information about inclusion/exclusion criteria and/or safet y or efficacy  parameters shall be 
suitably  calibrated and maintained to ensure that the data obtained is reliable and/or 
reprodu cible.  Documentation of equipment calibration must be retained as source 
documentation at the trial site.
Critical Equipment for this trial includes:
2°C to 8°C refrigerator with temperature -monitoring device
–20°C freezer with temperature -monitoring device
Centrifuge
Visit Requirements 7.1.5
Visit requirements are outlined in Section 6.0-Trial Flow Chart. Specific procedure -related 
details are provided above in Section 7.1 -Trial Procedures.
Screening [IP_ADDRESS]
Screening procedures will be performed at Visit 1 . Aseparate screening visit is not required.
Vaccination Visits [IP_ADDRESS]
See Section 6.[ADDRESS_205392]-trial(Visit 4 : Follow -up Visit, and Visit 5: Follow -up Phone Call) [IP_ADDRESS]
Visit 4Follow -up Visit : Subjects will be required to return to the clinic 6to 8 weeks after 
Vaccination 2 .
Visit 5Follow -up Phone Call: In addition, [ADDRESS_205393] a causal relationship with this treatment . An adverse event can therefore be any 
unfavourable and unintended sign (including an abnormal laboratory  finding, for example),  
  04S63N 
  055D6R
Product:   V210 38
Protocol/Amendment No.: A03-[ADDRESS_205394] or protocol -
specified procedure.  Any worsening (i.e., any clinically  significant adverse change in 
frequency  and/or intensity ) of a preexisting condition that is temporally  associated with the 
use of the Sponsor ’s product, is also an adverse event.
Changes resulting from normal growth and development that do not vary significantl y in 
frequency  or severit y from expected levels are not to be considered adverse events.  
Examples of this may include, but are not limited to, teething, typi[INVESTIGATOR_26336] a ph ysiologically  appropriate time.
Sponsor's product includes any pharmaceutical product, biological product, device, 
diagnostic agent or protocol -speci fied procedure, whether investigational (including placebo 
or active comparator medication) or marketed, manufactured by, licensed by, provided by [CONTACT_75365].
Adverse events may occur during clinical trials, or as prescribed in clinical practice, from 
overdose (whether accidental or intentional), from abuse and from withdrawal.
All adverse events that occur after the consent form is signed but before 
allocation/ randomization must be reported by [CONTACT_105943], or are the result of a protocol -specified intervention, including but 
not limited to washout or discontinuation of usual therap y, diet, placebo treatment or a 
procedure. From the time of allocation/rando mization through 14 days (42 days for live 
attenuated vaccines) following the first vaccination(s) and from the time of any subsequent 
vaccination(s) through 14 days (42 days for live attenuated vaccines) thereafter, all adverse 
events must be reported by [CONTACT_093]. Such events will be recorded at each 
examination on the Adverse Event case report forms/worksheets. The reporting timeframe 
for adverse events meeting any serious criteria is described in Section [IP_ADDRESS]. The 
investigator will make every  attempt to follow all subjects with non-serious adverse events 
for outcome.
Electronic reporting procedures can be found in the Electronic Data Capture (EDC )data 
entry  guidelines. Paper reporting procedures can be found in the Investigator Trial File 
Bind er (or equivalent).
Definition of an Overdose for This Protocol and Reporting of Overdose to the 7.2.1
Sponsor
In this trial, an overdose is any dose higher than 1dose of trial vaccine administered within 
24 hours .
If an adverse event(s) is associated with (“re sults from”) the overdose of Sponsor's product or 
vaccine, the adverse event(s) is reported as a non-serious adverse event, unless other serious 
criteria are met.
If a dose of Sponsor's product or vaccine meeting the protocol definition of overdose is taken 
without any associated clinical symptoms or abnormal laboratory  results, the overdose is  
  04S63N 
  055D6R
Product:   V210 39
Protocol/Amendment No.: A03-[ADDRESS_205395]-2017
Confidentialreported as a non-serious adverse event using the terminology  “accidenta l or intentional 
overdose without adverse effect.”
All reports of overdose with and without an adverse event must be reported by [CONTACT_23514] 24 hours to the Sponsor either by [CONTACT_26365]. Electronic 
reporting procedures can be found in the EDC data entry  guidelines. Paper reporting 
procedures can be found in the I nvestigator Trial File Binder (or equivalent) .
Immediate Reporting of Adverse Events to the Sponsor 7.2.2
Serious Adverse Events [IP_ADDRESS]
A serious adverse event is any adverse event occurring at any dose or during any use of 
Sponsor's product that:
●Results in death;
●Is life threatening;
●Results in persistent or significant disability /incapacity ;
●Results in or prolongs an existing inpatien t hospi[INVESTIGATOR_059];
●Is a congenital anomal y/birth defect;
●Is an other important medical event .
Note: In addition to the above criteria, adverse events meeting either of the below criteria, 
although not serious per ICH definition, are reportable to the Sponsor in the same timeframe 
as SAEs to meet certain local requirements. 
●Is a cancer;
●Is associate d with an overdose.
Refer to Table 2for additional details regarding each of the above criteria.  
For the time period beginning when the consent form is signed until treatment 
allocation/ randomization, any serious adverse event, or follow up to a serious adverse event, 
including death due to any  cause, that occurs to any  subject must be reported within [ADDRESS_205396] to be excluded from the trial, or is the result of a 
protocol -specified intervention, including but not limited to washout or discontinuation of 
usual therap y, diet, placebo treatment or a procedure.
For the time period beginning at treatment allocation/ randomization through 6 months 
(~180 days) following the second vaccination , any serious adverse event, or follow up to a 
serious adverse event, including death due to any cause, whether or not related to the 
Sponsor's product, must be reported within 24 hours to the Sponso reither by [CONTACT_26366]. Electronic reporting procedures can be found in the EDC data entry  
guidelines. Paper reporting procedures can be found in the Investigator Trial File Binder (or 
equivalent). 
  04S63N 
  055D6R
Product:   V210 40
Protocol/Amendment No.: A03-[ADDRESS_205397] be reported immediately  to the Sponsor if the event is either:
1. A death that occurs prior to the subject completing the trial, but outside the time period 
specified in the previous paragraph.
or
2. A serious adverse event that is considered by  [CONTACT_19427] a qualified phy sician 
to be vaccine related.
All subjects with serious adverse events must be followed up for outcome.
Events of Clinical Interest [IP_ADDRESS]
Selected non-serious and serious adverse events are also known as Eve nts of Clinical I nterest 
(ECI) and must be reported to the Sponsor.
For the time period beginning when the consent form is signed until treatment 
allocation/ randomization, any  ECI, or follow up to an ECI , that occurs to any  subject must be 
reported within [ADDRESS_205398] to be excluded from the trial, 
or is the result of a protocol -specified inter vention, including but not limited to washout or 
discontinuation of usual therap y, diet, placebo treatment or a procedure.
For the time period beginning at treatment allocation/ randomization through 14days 
following cessation of treatment, any ECI, or fol low up to an ECI, whether or not related to 
the Sponsor’s product, must be reported within 24 hours to the Sponsor, either by [CONTACT_26366].  Electronic reporting procedures can be found in the EDC data entry 
guidelines.  Paper reporting proced ures can be found in the Investigator Trial File Binder (or 
equivalent).
Events of clinical interest for this trial include:
No ECI s are being collected for this trial.
Evaluating Adverse Events 7.2.[ADDRESS_205399] to 
the elements outlined in Table 2. The investigator’s assessment of causality  is required for 
each adverse event.  Refer to Table 2for instructions in evaluating adverse events. 
  04S63N 
  055D6R
Product:   V210 41
Protocol/Amendment No.: A03-[ADDRESS_205400]-2017
ConfidentialTable 2 Evaluating Adverse Events
Maximum Mild awareness of sign or symptom, but easily tolerated (for pediatric trials, awareness of symptom, but easily tolerated)
Intensity Moderate discomfort enough to cause interference with usual activity (for pediatric trials, definitely acting like something is wrong)
Severe incapacitating with inability to work or do usual activity (for pediatric trials, extremely distressed or unable to do usual activities) 
Injection site redness or swelling from the day of vaccination through Day 5post-vaccination will be evaluated by [CONTACT_75367].
Seriousness A serious adverse event (AE) is any adverse event occurring at any dose that:
†Results in death; or
†Is life threatening; orplaces the subject, in the view of the investigator, at immediate risk of death from the event as it occurred [Note: This does not include an 
adverse event that, had it occurred in a more severe form, might have caused death.]; or
†Results in a persistent or significant disability/incapacity (substantial disruption of one’s ability to conduct normal life functions); or
†Results in or prolongs an existing inpatient hospi[INVESTIGATOR_059] (hospi[INVESTIGATOR_19357], regardless of length of stay, even if the 
hospi[INVESTIGATOR_2138] a precautionary meas ure for continued observation. ( Note: Hospi[INVESTIGATOR_19358] a pre-existing condition that has not 
worsened is not a serious adverse event.  A pre -existing condition is a clinical condition that is diagnosed prior to the use of a [COMPANY_006] product and is documented in the 
patient’s med ical history. ); or
†Is a congenital anomaly/birth defect   (in offspring of subject taking the product regardless of time to diagnosis); or
Is a cancer (although not serious per ICH definition, is reportable to the Sponsor within 24 hours to meet certain local requirements; or
Overdose, although not serious per ICH definition, whether accidental or intentional, with or without an accompanying adverse event/serious adverse event, is
reportable to the Sponsor within [ADDRESS_205401] and may require medical or surgical intervention to prevent one of the outcomes listed 
previously (designated above by a †).
Duration Record the start and stop dates of the adverse event.  If less than [ADDRESS_205402] vaccine to be discontinued?
Relationship 
to test vaccine Did the test va ccine cause the adverse event? The determination of the likelihood that the test vaccine caused the adverse event will be provided by [CONTACT_75368] a qualified physician.  The investigator’s signed/dated initials on the source document or worksheet that supports the causality noted on the AE form, ensures that a 
medically qualified assessment of causality was done.  This initialed document must be retained for the required regulatory t ime frame.  The criteria below are intended 
as reference guidelines to assist the investigator in assessing the likelihood of a relationship between the test vaccine and the adverse event based upon the available 
information.  
The following components are to be used to assess the relationship between the test vaccine and the AE; the greater the co rrelation with the components and their 
respective elements (in number and/or intensity), the more likely the test vaccine caused the adverse event:
Exposure Is there evidence that the subject was actually exposed to the test vaccine such as:  reliable history, acceptable compliance assessment 
(e.g., diary), seroconversion or identification of vaccine virus in bodily specimen?
Time Course Did the AE follow in a reasonable temporal sequence from administration of the test vaccine? 
Is the time of onset of the AE compatible with a vaccine -induced effect?
Likely Cause Is the AE not reasonably explained by [CONTACT_26369], other drug(s)/vaccine(s), or other host or
environmental factors 
  04S63N 
  055D6R
Product:   V210 42
Protocol/Amendment No.: A03-[ADDRESS_205403] vaccine and the AE:  (continued)
to test vaccine Dechallenge (not applicable for vaccines)
(continued) Rechallenge Was the subject reexposed to the test vaccine in this trial?
      If yes, did the AE recur or worsen?
          If yes, this is a positive rechallenge.    If no, this is a negative rechallenge.
(Note:  This criterion is not applicable if:  (1) the initial AE resulted in death or permanent disability, or (2) the trial is a single -dose 
vaccine trial.)
NOTE:  IF A RECHALLENGE IS PLANNED FOR AN ADVERSE EVENT WHICH WAS SERIOUS AND WHICH MAY HAVE 
BEEN CAUSED BY [CONTACT_75369], OR IF REEXPOSURE TO THE TEST VACCINE POSES ADDITIONAL POTENTIAL 
SIGNIFICANT RISK TO THE SUBJEC T, THEN THE RECHALLENGE MUST BE APPROVED IN ADVANCE BY [CONTACT_26371]/INDEPENDENT ETHICS COMMITTEE.
Consistency with Trial 
Vaccine ProfileIs the clinical/pathological presentation of the AE consistent with previous knowledge regarding the test vaccine or vaccine class 
pharmacology or toxicology?
The assessment of relationship will be reported on the case report forms /worksheets by [CONTACT_19427] a qualified ph ysician according to his/her best clinical judgment, including 
consideration of the above elements.  
Record one of the following: Use the following criteria as guidance (not all criteria must be present to be indicative of a vaccine relationship) .
Yes, there is a reasonable possibility of 
vaccine relationship.There is evidence of exposure to the test vaccine.  The temporal sequence of the AE onset relative to the administration of t he test vaccine 
is reasonable.  The AE is more likely explained by [CONTACT_75370].
No, there is not a reasonable possibility of 
vaccine relationshipSubject did not receive the test vaccine OR temporal sequence of the AE onset relative to administration of the test vaccine is not 
reasonable OR the AE is more likely explained by [CONTACT_26372]’s product .  (Also entered for a subject with overdose 
without an associated AE.) 
  04S63N 
  055D6R
Product:   V210 43
Protocol/Amendment No.: A03-[ADDRESS_205404]-2017
ConfidentialSponsor Responsibility for Reporting Adverse Events 7.2.4
AllAdverse Events will be reported to regulatory authorities, IRB/IECs and investigators in 
accordance with all applicable global laws and regulations , i.e., per ICH Topic E6 (R1) 
Guidelines for Good Clinical Practice .
8.0STATISTICAL ANALYSIS PLAN
This section outlines the statistical analy sis strategy  and proce dures for the trial. If, after the 
trial has begun, but before any final database lock,changes made to primary  and/or key 
secondary  hypotheses, or the statistical methods related to those hypotheses, then the 
protocol will be amended (consistent with ICH Guideline E-9).  Chan ges to exploratory  or 
other nonconfirmatory  analyses made after the protocol has been finalized, but before final 
database lock, will be documented in a supplemental statistical analysis plan and referenced 
in the Clinical Study  Report (CSR) for the trial.  Post hoc exploratory  analyses will be clearly 
identified in the CSR.
Statistical Analysis Plan Summary 8.1
Key elements of the statistical analy sis plan are summarized below; the comprehensive plan 
is provided in Sections 8.2through 8.11.
Study Design Overview A Phase 3, Double -Blind, Randomized, Multicenter, Controlled Study to 
Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX™
Passage Extension 34 (PE34) Process Administered Concomitantly with 
M-M-R™II
Treatm entAssignment This is a double -blind trial with 2vaccination groups. Subjects will be 
randomized to VARIVAX™PE34 process group and VARIVAX™([ADDRESS_205405]) group with the ratio 1:1.
Analysis Populations Immunogenicity: P er-protocol (PP) and Full Analysis Set (FAS)
Safety : All Subjects as Treated (ASaT)
Prim ary Endpoint(s) 1.Theresponse rate, the proportion of subjects w ith VZV antibody 
titer 5 gpELISA units/mL 6 weeks Postvaccination 1among 
subjects who were seronegative to VZV (titer <1.25 gpELISA 
units/mL) at baseline.
2.The GMT of VZV antibodies in subjects at 6 w eeks 
Postvaccination 1.
Key Secondary Endpoints The seroconversion rate, the proportion of subjects with VZV antibody 
titer 1.25 gpELISA units/mL 6 w eeks Postvaccination 1among subjects 
who were seronegative to VZV (titer <1.25 gpELISA units/mL) at 
baseline.
Statistical Methods for Key 
Efficacy /Immunogenicity/ 
Pharm acokinetic AnalysesFor the prim ary hypothesis 1, VARIVAX ™PE34 process will be 
considered noninferior to VARIVAX ™([ADDRESS_205406]) if 
the lower bound of the 2-sided 95% CIof difference in response rates
(VARIVAX ™PE34 process minus VARIVAX ™ [ [ADDRESS_205407] ])excludes a decrease of 10 percentage points or more.  This 
analysis will be assessed using the Miettinen and Nurminen method [17].
For the prim ary hypothes is2, VARIVAX ™PE34 process will be 
considered noninferior to VARIVAX ™([ADDRESS_205408]) if 
the lower bound of the 2-sided 95% CIof the GMT ratio (VARIVAX ™
PE34 process /VARIVAX ™[[ADDRESS_205409]] )is >0.67.   This  
  04S63N 
  055D6R
Product:   V210 44
Protocol/Amendment No.: A03-[ADDRESS_205410] based on the 
log-transformed Postvaccination 1antibody titers.
For the prim ary hypothesis 3, VARIVAX ™PE34 process will be 
considered acceptable if the lower bound of the 95% CI for the response 
rate is above 76.0%.   This analysis will be assessed using the exact CI 
method for a single binomial proportion given in Collett [18].
Statistical Methods for Key 
Safety AnalysesThe analysis of safety results will follow a tiered approach. The tiers 
differ with respect to the analyses that will be performed.
Tier 1 safety endpoints include the rate of fever (temperature ≥102.2°F 
[≥39.0°C] oral equivalent) from Days 1 to 42 after each vaccination; 
varicella -, zoster -, measles -,or rubella -like rashes or mumps -like 
symptoms , and injection -site rashes occurring within Days 1 to 42 after 
each vaccination; and solicited injection -site reactions (redness, swelling, 
pain/tenderness) with in Days 1 to 5 after each vaccination. For Tier 1 
events, inferential testing for statistical significance with pvalues and 
95% CIs will be provided for betw een-group comparisons.
Any adverse experiences (specific terms as well as system orga n class 
[SOC] terms) that are not pre -specified as endpoints of particular interest 
will be classified as belonging to Tier 2 or Tier 3. Tier 2 parameters will 
be assessed via point estimates with 95% CIs provided for betw een-
group comparisons; only point estimat es by [CONTACT_176005] 3 safety parameters.   Analyses will be performed using 
theMiettinen and Nurminen method [17].
Interim Analyses No interim analyses are planned for this trial.
Multiplicity No multiplicity adjustment is planned as success of the trial requires 
success on both the noninferiority and acceptability hypotheses.
Sample Size and Power The planned sample size is ~600 subjects in total (~300 in each group) . 
Assuming 8 0% evaluability, 90% Postvaccination 1response rates, and a 
standard deviation of 1.2 for the log -transformed Postvaccination 1
antibody titers, this trial has 94.1% pow er for demonstrating 
noninferiority of the response rate, 95.8% pow er for demonstrating 
noninferiority of the GMT, and >99.9% pow er for demonstrating 
acceptability of the response rate at an overall 2-sided 5% α-level. The 
overall pow er for the primary immunogenicity hypotheses is estimate d to 
be 90% (= 0.941 × 0.958 × >0.999).
Responsibility for Analyses/In -house Blinding 8.2
The statistical analysis of the data obtained from this trial will be the responsibility  of the 
Clinical Biostatistics department of the S ponsor .
This trial will be cond ucted as a double -blind trial under in-house blinding procedures. The 
official final database will not be unblinded until medical/scientific review has been 
performed, protocol violators have been identified, and data have been declared final and 
complete .
The Clinical Biostatistics department will generate the randomized allocation schedule(s) for 
trialtreatment assignment. 
  04S63N 
  055D6R
Product:   V210 45
Protocol/Amendment No.: A03-[ADDRESS_205411]-2017
ConfidentialHypotheses/Estimation 8.[ADDRESS_205412] dose of VARIVAX™ in subjects who were in itially  seronegative to 
VZV at baseline.
The response rate and GMT endpoints and the criteri afor baseline seronegativity  are defined 
below:
The response rate is the percent age of subjects with VZV antibody  titer 
≥5gpELISA units/mL  6weeks Postvaccination 1among subjects who were 
seronegative to VZV (titer <1.25 gpELISA units/mL ) at baseline.
The postvaccination antibody  GMTs 6 weeks Postvaccination 1.
In addition, the VZV seroconversion rate (defined as the proportion of subjects with baseline 
VZV titer <1.25 gpELISA units/mL and with postvaccination VZV titer ≥1.25 
gpELISA units/mL) will be summarized after the first dose.  For subjects who are initially 
seropositive (baseline VZV antibody  titer ≥1.25 gpELISA units/mL ), the geometric mean 
fold rise (GMFR ) and the percent ageof subjects achieving ≥4-fold rise in antibody  titer from 
baseline will be summarized after the first dose.
Safety Endpoints 8.4.2
Refer to Section [IP_ADDRESS] for the description of the safet y measures in this trial.
The key safet y endpoints evaluated as Tier 1 events areas follows : the rate of elevated 
temperature from Days 1 to 42 after each vaccination; varicella -, zoster -, measles -,or 
rubella -like rashes or mumps -like symptoms ,and all injection -site rashes occurring within 
Days1 to 42 after each vaccination , and all solicited injection -site reaction s(redness, 
swelling, pain/tenderness) occurring within Day s1 to 5 after each vaccination.
Analysis Populations 8.5
Immunogenicity Analysis Populations 8.5.1
Per-protocol Population [IP_ADDRESS]
The primary  immunogenicity  analyses will be based on the PP population.  The 
PPpopulation consists of those subjects who are not considered as protocol violators .  
Violations include but are not limited to:failure to receive the full, scheduled doses (atleast  
  04S63N 
  055D6R
Product:   V210 46
Protocol/Amendment No.: A03-[ADDRESS_205413]-2017
Confidential90days between doses 1 and 2)of correct clinical materia land lack of valid serology  results 
available from [ADDRESS_205414] dose.   The day range for inclusion of 
postvaccination blood samples in the statistical analysis is wider than the visit window 
provided earlier in this protocol (+ 14days for the 6 -week serology  testing), but is being used 
to be consistent with other studies evaluating VZV -containing vaccines.
In addition to meeting the PP population requirements, the primar y analysis requires specific 
baseline criteria be met for VZV:  baseline VZV antibod y titer <1.25 gpELISA units/mL .  
Additional immunogenicity  summaries will be made for subjects who meet the PP population 
requirements but do not meet the baseline antibody requirement for VZV ( e.g., a summary  of 
Postvaccination 1VZV immunogenicit y in otherwise PP subjects who have a baseline VZV 
antibody  titer ≥1.25 gpELISA units/mL; see S ection [IP_ADDRESS] for details).
Supportive summaries at Postvaccination 1will also be made for the PP population, as 
described in Section [IP_ADDRESS] .
The final determination on protocol violations, and thereby  [CONTACT_176006], will be made before unblinding of the database and will bedocumented in a 
separate memo.
Full Analysis Set [IP_ADDRESS]
A supportive summary  and anal ysis for VZV immunogenicit y will be based on the FAS.  The 
FAS population consists of all randomized subjects with a valid serology  measurement, 
regardless of protocol violations.  Subjects will be included in the vaccination group to which 
they are randomized for the FAS population.  As a supportive analy sis, the primary  
immunogenicit y hypotheses will be evaluated on the FAS population in subjects meeting the 
VZV baseline antibody requirement to assess the robustness of the primary conclusions 
based on the PP population.
Safety Analysis Population 8.5.2
The ASaT population will be used for the analysis of safet y data in this trial.  The ASaT 
population consists of all randomized/allocated subjects who received at least 1dose of trial
treatment. Subjects will be included in the treatment group corresponding to the trial
treatment they actuall y received for the analy sis of safety  data using the ASaT population.  
For most subjects this will be the treatment group to which they are randomized.  Subjects 
who take incorrect trial treatment for the entire treatment period will be included in the 
treatment group corresponding to the trial treatment actuall y received (e.g., a subject who 
was randomized to Group 1 but received all vaccines according to the Group 2 schedule will 
be summarized with Group 2 subjects).   Subjects who receive a mixed regimen (e.g., 
received VARIVAX ™PE34 process at Visit 1, but received VARI VAX™ [[ADDRESS_205415] ] at Visit 3) will have their Postvaccination 1safet y data summarized 
with the group corresponding to the vaccine(s) received (for this example, with Group 1 
subjects), and subsequent safet y data summarized separatel y from the Postvaccination [ADDRESS_205416]:   V210 47
Protocol/Amendment No.: A03-[ADDRESS_205417]-2017
ConfidentialStatistical Methods 8.6
To control the overall type I error rate at α =0.025 (1-sided) and since success of the trial
requires success on 3hypotheses (2 non inferiority  and 1acceptability), each individual 
hypothesis test will be eva luated at α =0.025 (1 -sided).
For the safet y analyses, unless otherwise specified, all statistical tests will be conducted at 
α =0.05 level ( 2-sided).
Statistical Methods for Immunogenicity Analysis 8.6.1
Noninferiority of Postvaccination 1VZV Antibody Response (Primar y [IP_ADDRESS]
Hypothesis 1)
For the primar y hypothesis concerning the noninferiorit y of the Postvaccination 1antibody  
response rate for recipi[INVESTIGATOR_175984]™ PE34 process compared with VARIVAX™ 
([ADDRESS_205418]) , a 1- sided test for non inferiority  in 2 binomi al proportions will be 
performed at the α =0.025 ( 1-sided) level.
The statistical hy pothesis thatwill be evaluated is:
H0: p1‒ p2≤ -δ versus H 1: p1‒ p2>-δ,
where H0is the null hypothesis, H1is the alternative hypothesi s, p1and p2are the true 
antibody  response rates for the subjects in VARI VAX™ PE34 process and control 
groups, respectivel y, and δ is the pre -specified difference between the 2 proportions.  The 
pre-specified difference between the 2 proportions (δ) is 0.10 (10 percen tage points).
This analy sis will be unstratified and the test statistic, pvalue, and corresponding 95% CIs 
will be calculated using the Miettinen and Nurminen method, an unconditional, asymptotic 
method [17].  The response rate in subjects receiving a single dose of VARI VAX™ PE34 
process will be considered noninferior to the control group if the 1-sided pvalue for the 
associated noninferiority test is <0.025.  This criterion is equivalent to requiring the lower 
bound of the 2-sided 95% CI for the difference in rates (Group 1 minus Group 2) exclude a 
decrease o f 10 percentage points or more.
This analy sis will be conducted on the PP population and the FAS population ;however ,the 
PP population is the primary  population for the assessment of the h ypotheses.
Noninferiority of Postvaccination 1VZV Antibody GMT (Primary Hypothesis [IP_ADDRESS]
2)
For the secondar y hypothesis concerning the noninferiority  of the Postvaccin ation 1VZV 
antibody ,GMT for recipi[INVESTIGATOR_175985]™ PE34 process compared with VARI VAX™ 
([ADDRESS_205419]) , a 1-sided test for noninferiority  in the VZV antibody  GMT will 
be performed at the α =0.025 level (1- sided). 
  04S63N 
  055D6R
Product:   V210 48
Protocol/Amendment No.: A03-[ADDRESS_205420]-2017
ConfidentialThe sta tistical hy pothesis for the non inferiority  of the antibody  GMT is:
H0:  GMT 1/GMT 2≤0.67 versus H 1:  GMT 1/GMT 2>0.67,
where GMT 1is the GMT for recipi[INVESTIGATOR_175986] 1 receiving VARIVAX™ PE34 process 
and GMT 2is the GMT for recipi[INVESTIGATOR_175986] 2 receiving VARIVAX™ ([ADDRESS_205421]) .  A ratio of 0.67 corresponds to a 1.5-fold decrease in GMT in 
Group 1 compared with Group 2.  Rejecting the null hypothesis (H0) at the 1-sided 
α
=0.025 level corresponds to the lower bound of the 2-sided 95% CI for the GMT ratio 
(Group 1/Group 2) being >0.67.
The GMT ratio (VARIVAX™ PE34 process /VARIVAX™ [ [ADDRESS_205422] ])
along with a 2-sided 95% CI and pvalue will be determined at week 6 Postvaccination 1.  
Assuming normality  of the log antibod y titers, a 2-sided 95% CI for the differ ence in the 
means of the log titers (VARIVAX™ PE34 process minus VARIVAX™ [[ADDRESS_205423] ])will be constructed based on the t-distribution.  The CI of the GMT ratio 
(VARIVAX™ PE34 process /VARIVAX™ [[ADDRESS_205424] ])will then be 
provided b y exponentiating the endpoints of the CI for the difference in log titers.
This analy sis will be conducted on the PPand FAS population s;however ,the PP population 
is the primary  population for the assessment of the hy potheses.
Acceptability of Immune Response (Primary Hypothesis 3) [IP_ADDRESS]
The primary  hypotheses also involve whether or not subjects in Group 1 of VARIVAX™ 
PE34 process demonstrate an acceptable antibody  response Postvaccination 1to VZV 
(Hypothesis 3).  An acceptable antibod y response to VZV is defined as a response rate that is 
at least 76.0%.  A  h ypothesis of H0: p≤p0will be tested against the alternative H1: p>p0, 
where p is the antibod y response rate after a single dose and p0is the hypothesized rate to be 
ruled out (76.0% for VZV).  A 1-sided, 1-sample exact binomial test will be conducted at 
α =0.025 significance level.  Rejection of the null hypothesis will lead to a conclusion of an 
acceptable antibody  response to VZV.  This is equivalent to the lower bound of the 1-sample 
2-sided 95% CI being >76.0%.  The 1-sample 2-sided CIs will be computed using the exact 
CI method for a single binomial proportion given in Collett [18].
This analy sis will be conducted on the PP population and the FAS population ;however ,the 
PP population is the primary  population for the assessment of the h ypotheses.
The strategy  to address multiplicity  issues with regard to multiple primary  immunogenicit y 
endpoints and primary  immunogenicit y hypothes es is described in Section 8.8 ‒Multiplicity .
Secondary Summaries [IP_ADDRESS]
In addition to the analy sisdescribed in Sections [IP_ADDRESS] ,[IP_ADDRESS] , and [IP_ADDRESS] supporting the 
primary  hypotheses, the following supportive summaries and figures will be presented for all 
subjects in the PP and FAS populations (where noted) with Postvaccination 1
immunogenicit y data collected: 
  04S63N 
  055D6R
Product:   V210 49
Protocol/Amendment No.: A03-[ADDRESS_205425]-2017
ConfidentialThe observed VZV antibody  response rates (the percent of subjects with VZV titer ≥5 
gpELISA units/mL) will be summarized by [CONTACT_176007] 1, 
along with 2- sided 95% CI s.  The CIs will be computed using the exact CI method for 
a single binomi al proportion given in Collett [18].  This will be computed on the 
PPpopulation of subjects (with baseline antibody  titer restriction) and the 
FAS population (with baseline antibody  titer restriction).
The observed VZV seroconversion rate (the percent of subjects with VZV titer 
≥1.25 gpELISA units/mL ) will be summarized by [CONTACT_176008] 1, along with 2-sided 95% CIs.  The CIs will be computed using the 
exact method for a single binomi al proportion given in Collett [18].  This will be 
computed on the PPpopulation of subjects (with baseline antibody  titer restriction) 
and the FAS population (with baseline antibody  titer restriction).
The observed VZV GMTs will be summarized by [CONTACT_176008] 1,along with 2-sided 95% CIs.  The GMTs will be calculated by 
[CONTACT_176009]-transformation of the antibody  titer, computing the arithmetic 
mean, and back -transforming.  The CIs for the GMTs will be based on the natural 
log-transformed titers and the t
-distribution.  This will be computed on the 
PPpopulation of subjects (with baseline antibody  titer restrictions) and on the 
FAS population (with baseline antibody  titer restrictions).
For subjects who are seropositive at baseline ( ≥1.25 gpELISA units/mL  for VZV), the 
following parameters and 95% CIs will be summarize d at Postvaccination 1by 
[CONTACT_43108]: the GMT, the antibody  response rate, the GMFR from baseline, 
and the percent of subjects with ≥4-fold rise in antibody  titer from baseline.  Similar 
methodology ,as described previously ,will be used for this summary .  This will be 
computed on the PP and FAS population s(in subjects with baseline VZV antibody 
titer ≥1.25 gpELI SA units/mL).  The CIs will only be calculated if there are at least 
5subjects who are seropositive to a respective antigen.
For subjects in the PP population only, graphical display s of the reverse cumulative 
distribution function of antibody  titers will be illustrated by  [CONTACT_43108].
The key  immunogenicity anal ysesare summarized in Table 
3. 
  04S63N 
  055D6R
Product:   V210 50
Protocol/Amendment No.: A03-[ADDRESS_205426]-2017
ConfidentialTable 3 Analy sis Strategy  for Key Immunogenicit yVariables
Endpoint/Variable
(Description, Time Point)Primary vs 
Supportive 
Approach † Statistical MethodAnalysis 
PopulationMissing Data 
Approach
Primary (Hypothesis 1 & 2):
Noninferiority of the
Postvaccination 1VZV 
antibody response rates in 
Group 1 compared w ith 
Group 2P (PP)
S (FAS)Miettinen and 
Nurminen ‡approach; 
tested at α =0.025 
(1-sided); corresponding 
95% CIs for risk 
differencePP
FASObserved data 
only
Noninferiority of the 
Postvaccination 1VZV 
antibody GMTs in Group 1 
compared with Group 2 P (PP)
S (FAS)2-sample mean 
difference and 95% CI 
and pvalues based on 
log-transformed titers 
and t -distributionPP
FASObserved data 
only
Primary (Hypothesis 3):
Acceptability of the 
Postvaccination 1VZV 
antibody response rate in 
Group 1P (PP)
S (FAS)Exact 1-sample b inomial; 
tested at α =0.025 ( 1-
sided); corresponding 
95% CIsPP
FASObserved data 
only
Secondary:
Summary of 
Postvaccination 1, VZV 
antibody response rates and 
VZV seroconversion rates 
for both groupsP (PP)
S(FAS)Exact 1-sample b inomial 
methodology, 95% CIsPP
FASObserved data 
only
Summary of 
Postvaccination 1VZV 
antibody GMTsP (PP)
S(FAS)1-sample mean and 95% 
CI based on 
log-transformed titers 
and t -distributionPP
FASObserved data 
only
Summary of 
Postvaccination 1VZV 
antibody response rates, 
GMT s, GMFR from baseline 
and % ≥ 4-fold rise from 
baseline in subjects initially 
seropositive for both groupsP (PP)
S(FAS)For rates, 1-sample 
binomial methodology, 
95% CI
For continuous variables, 
one-sample mean and 
95% CI based on t -
distributionPP
FASObserved data 
only
†P = p rimary approach; S = supportive approach.
‡Miettinen and Nurminen method [17]. 
  04S63N 
  055D6R
Product:   V210 51
Protocol/Amendment No.: A03-[ADDRESS_205427]-2017
ConfidentialStatistical Methods for Safety Analysis 8.6.2
Safety  and tolerability  will be assessed by [CONTACT_176010].
The analysis of safet y results will follow a tiered approach (Table 4).  The tiers differ with 
respect to the analyses that will be performed.  Safety  parameters or adverse experiences of 
particular interest that are identified a priori constitute “Tier 1” safet y endpoints that will be 
subject to inferential testing for statistical significance with pvalues and 95% CIs provided 
for between -group comparisons.  Other safety  parameters will be considered Tier 2 or Tier 3.  
Tier 2 parameters will be assessed via point estimates with 95% CIs provided for 
between -group comparisons; only point estimates by [CONTACT_176011] 3 safety  parameters.
Any adverse experiences (specific terms as well as system organ class [SOC] terms) that are 
not pre -specified as endpoints of particular interest will be classified as belonging to Tier [ADDRESS_205428] 
4subjects in any vaccinat ion group exhibit the event; all other adverse experiences will 
belong to Tier 3.
The threshold of at least 4 events was chosen because the 95% CIfor the between -group 
difference in percent incidence will alway s include zero when treatment groups of equal size 
each have less than 4 events and,thus,would add little to the interpretation of potentiall y 
meaningful differences. Because many 95% CIsmay be provided without adjustment for 
multiplicity , the CIsshould be regarded as a helpful descriptive measure to be used in 
review, not a formal method for assessing the statistical significance of the between -group 
differences in adverse experiences and predefined limits of change.
For this protocol, the follow ing are considered Tier 1 events: elevated temperatures 
(maximum reported temperature ≥102.2°F [≥39.0°C] oral equivalent) within Days1 to 42 
after each vaccination; vaccine -specific measles -, rubella -, varicella -, zoster -like rashes , 
mumps -like symptoms, and injection -site rashes occurring within Days1 to 42 after each 
vaccination; and solicited injection -site reactions (redness, swelling, pain/tenderness) within 
Days1 to [ADDRESS_205429] clinical categories consisting of the 
percentage of subjects with any adverse experience, a vaccine -related adverse experience, a 
serious adverse experience, an adverse experience that is both vaccine -related and serious, 
and who discontinued due to an adverse experience will be considere d Tier 2 endpoints.  The 
pvalues (Tier 1 onl y) and 95% CIs (Tier 1 and Tier 2) will be provided for between -group 
differences in the percentage of subjects with events; these analyses will be performed using 
the Miettinen and Nurminen method, an unconditi onal, asymptotic method [17].
Extended Safety  Follow -up Period (Day  133[+14 day s] to Day  271 [+14 day s])
For the extended safet y follow -up period, a summary  will be provided of the number of 
subjects in each vaccination group who report a serious adverse experience or a medically 
attended adverse experience.  For this extended safet y follow -up period, these events will be 
treated as Tier 2 events, with 95% CI s being presented for the between -group risk differenc es 
in the percentage of subjects reporting these events.  For serious adverse experiences, a  
  04S63N 
  055D6R
Product:   V210 52
Protocol/Amendment No.: A03-[ADDRESS_205430]-2017
Confidentialsummary  along with a between- group comparison will also be provided for the entire trial
(i.e., from enrollment through 180 day s Postvaccination 2).
Because many 95% CIs may be provided without adjustment for multiplicity , the CIs should 
be regarded as a helpful descriptive measure to be used in review, not a formal method for 
assessing the statistical significance of the between- group differences in adverse experiences.
Table 4 Analy sis Strategy for Safety  Parameters
Safety Tier Safety Endpoint†pValue95% CI for 
Treatment 
Com parisonDescriptive 
Statistics
Tier 1Rate of elevated temperatures
(102.2 F [39.0 C])‡
from Days 1 to 42 postvaccinationX X X
Vaccine- specific systemic rashes 
(measles -like, rubella -like, va ricella -
like, zoster -like), mumps -like 
symptoms, and injection -site rashes
Days1 to 42 postvaccinationX X X
Injection -sitereactions (redness, 
swelling, and pain/tenderness )Days1 
to 5postvaccinationX X X
Tier 2Any AE Days 1 to 42 postvaccination X X
Any serious AE Days 1 to 42 
postvaccinationX X
Any vaccine -related§AEDays 1 to 42 
postvaccinationX X
Any serious and vaccine -related§AE
Days 1 to 42 postvaccinationX X
Discontinuation due to AE Days 1 to 
42 postvaccinationX X
Specific systemic AEs¶and SOCs
(incidence ≥4 subjects in one of the 
vaccination groups) during Day s 1 to 
42 postvaccination and injection -site 
reactions¶(incidence ≥4 subjects in 
one of the vaccination groups) Day s1 
to [ADDRESS_205431]:   V210 53
Protocol/Amendment No.: A03-[ADDRESS_205432]-2017
ConfidentialSafety Tier Safety Endpoint†pValue95% CI for 
Treatment 
Com parisonDescriptive 
Statistics
Tier 3Specific systemic AEs¶and SOCs 
(incidence < 4 subjects in allof the 
vaccination groups) during Day s 1 to 
42 postvaccination and injection -site 
reactions¶(incidence < 4 subjects in all
of the vaccination groups) Days 1 to 5 
and Days1 to 42 postvaccinationX
Maximum temperature summary 
(Brighton Collaboration Cutpoints) by 
[CONTACT_176012] : Days 1 to 42, Days 1 to 5, 
Days 6 to 13, Days 14 to 28, and Days 
29 to 42 postvaccinationX
Distribution of maximum size (for 
injection -site redness and swelling
Days 1 to 5 postvaccination) and 
distribution of maximum intensity (for 
all other injection -site reactions
Days1 to 5 postvaccination and all 
systemic AEs Days 1 to 42
postvaccination )X
† Adverse e xperience references refer to Clinical AEs.
‡ For reporting purposes, temperature swill be converted to oral equivalent by [CONTACT_1583] 1.0°F to axillary 
temperatures and subtracting 1.0°F from rectal temperatures.
§Determined by [CONTACT_176013].
¶Includes only those endpoints not pre -specified as Tier 1 or not already pre -specif ied as Tier -2 endpoints.
X =results will be provided .
The between -group comparisons described above will be made between Group 1 and 
Group 2 for each postvaccination follow-up period.  This will be done by [CONTACT_176014]™ PE34 process and VARI VAX™ ([ADDRESS_205433]) vaccination groups for the [ADDRESS_205434] vaccination 
and for the 42 days after receipt of the second vaccination. For serious adverse experiences, 
a summary  along with a between -group comparison will also be provided for the entire 
primary  trial phase (i.e., the combined 42 -day periods after both vaccinations).
Summaries of Baseline Characteristics, D emographics, and Other Analyses 8.6.[ADDRESS_205435] characteristics of age, gender, and race/ethnicity  will be summarized by [CONTACT_176015].  In addition, baseline serostatus for VZV will be 
presented b y vaccination group.
The number (%) of subjects with specific prior medications in any vaccination group within 
[ADDRESS_205436] vaccination will be summarized by [CONTACT_43108].  Also, the 
number (%) of subjects with specific prior vaccinations (incidence rate >0% in any 
vaccination group) within [ADDRESS_205437]:   V210 54
Protocol/Amendment No.: A03-[ADDRESS_205438]-2017
ConfidentialThe number (%) of subjects with specific concomitant medications (incidence rate ≥5% in 
any vaccination group) within 42days after each visit will be summarized by [CONTACT_176016].  Also, the number (%) of subjects with specific concomitant vaccinations (incidence 
rate >0% in any vaccination group) within [ADDRESS_205439] accounting will also indicate 
the nu mber of subjects who completed the trial.
No other anal yses are planned for this trial.
Interim Analyses 8.7
No interim analyses are planned for this trial.
Multiplicity 8.8
Because success of the trial r equires success on both the noninferiorit y and acceptabilit y
hypotheses, no adjustment for multiplicity  is required across the h ypothesis tests.
Sample Size and Power Calculations 8.9
Sample Size and Power for Immunogenicity Analyses 8.9.1
This trial will randomize ~300 subjects into Group 1 (VARI VAX™ PE34 process ) and 
~300 subjects into Group 2 (VARIVAX™ [[ADDRESS_205440] ]),and this trial has 
94.1% power for demonstrating noninferiorit y of the VZV response rate, 95 .8% power for 
demonstrating noninferiority  for antibody  GMTs ,and >99.9% power for demonstrating 
acceptability  of the VZV response rate at an overa ll 1-sided 2.5% α -level.
The sample size and power calculations are based on the following assumptions:
10% of subjects will be nonevaluable after the first vaccination (due to los tto 
follow -up or other r easons, excluding baseline VZV serostatus),
For the VZV analysis, 10% will have baseline VZV antibody  titers 
>1.25 gpELISA units/mL, resulting in an expected overall nonevaluability rate for the 
VZV Postvaccination 1primary  anal yses of 20% ( =10% +10%), and
The expected VZV Postvaccination 1response rate in both groups is assumed to be 
90% based on prior experience with VARIVAX™ in this age group.
The assumed standard deviation of the log-transformed VZV antibod y titer is 1.2 
based on previous studies of VARIVAX™. 
  04S63N 
  055D6R
Product:   V210 55
Protocol/Amendment No.: A03-[ADDRESS_205441]-2017
ConfidentialIf the assumptions listed above are observed at the final analy sis, the lower bounds for the 
95% CIs for addressing the 3 primary  hypotheses listed in Section 8.6.1 would be −5.4%for 
the noninferiorit y of response rates comparison (Hypothesis 1), 0.81 for the noninferiority  of 
GMTs comparison (Hypothesis 2), and 86.2% for the acceptability  of the response rate 
(Hypothesis 3).
Because success of the trial requires that the statistical criteria be met for both the 
noninferiority  and acceptability hypotheses, the overall power for the primary  
immunogenicit y hypotheses is estimated to be 90% ( =0.941 × >0.999 × 0.958).
Sample Size and Power for Safety Analyses 8.9.2
For safet y comparisons Postvaccination 1, all subjects are expected to be evaluable. If no 
serious adverse event is observed among the 300 subjects in each vaccination group, this trial 
provides 97.5% confidence that the true serious adverse event rate is <1.22% (1 out of every 
81subjects).
The probability  of observing at least 1serious adverse event in this trial depends on the 
number of subjects enrolled and the incidence rate of serious adverse events in the general 
population.  I f the incidence rate of a serious adverse event is 1 of every  186 recipi[INVESTIGATOR_75310] (0.54%), then there is an 80% chance of observing at least 1such serious adverse 
event among 300 subjects in the vaccine group. If the incidence rate is 1 of every 
433recipi[INVESTIGATOR_840] (0.23%), there is a 50% chance of observing at least 1serious adverse event.
For safet y comparisons, risk differences between any 2 vaccination groups that could be 
detected with an 80% probability  are summarized in Table 5for a variety  of hy pothetical t rue 
incidence rates.  These calculations assume there are 300 subjects for safety  in both groups 
and are based on a 2-sided significance level of α =0.05.  No multiplicity  adjustments were 
made in these calculations.
Table 5 Differences in Incidence of Adverse Event Rates between the Two Vaccination 
Groups That Can be Detected With an ~80% Probability  and a Two- Sided 
Significance Level of 0.05 Postvaccination 1
True Incidence Rate of Adverse 
Events in the Control Group 
(Group 2)True Incidence Rate of Adverse 
Events in the Investigational Group 
(Group 1)Detectable Percentage 
Point Difference in 
Incidence Rates of 
Adverse 
Events
N =300 N =300
1% 4.8% 3.8
2% 6.6% 4.6
5% 11.2% 6.2
10% 17.9% 7.9
15% 24.0% 9.0
20% 29.9% 9.9
30% 40.9% 10.[ADDRESS_205442]:   V210 56
Protocol/Amendment No.: A03-[ADDRESS_205443]-2017
ConfidentialFor safet y comparisons Postvaccination 2, it is expected that ~5% of subjects will fail to 
return for the second vaccination phase, which results in 285 subjects in each group. If no 
serious adverse event is observed among the 285 sub jects in each vaccination group, this trial 
provides 97.5% confidence that the true serious adverse event rate is <1.29% (1 out of every 
77subjects).
The probability  of observing at least 1serious adverse event in this trial depends on the 
number of subjects enrolled and the incidence rate of serious adverse events in the general 
population.  I f the incidence rate of a serious adverse event is 1 of every  177 recipi[INVESTIGATOR_75310] (0.56%) , then there is an 80% chance of observing at least 1such serious adverse 
event among 285 subjects in the vaccine group. If the incidence rate is 1 of every 
411recipi[INVESTIGATOR_840] (0.24%), there is a 50% chance of observing at least 1serious adverse event.
For safet y comparisons, risk differences between any 2 vaccination groups that could be 
detected with an 80% probability  are summarized in Table 6for a variety  of hy pothetical true 
incidence rates.  These calculations assume there are 285 subjects for safety  in both groups 
and are based on a 2-sided significance level of α =0.05.  No multiplicity  adjustments were 
made in these calculations.
Table 6 Differences in Incidence of Adverse Event Rates Between the Two Vaccination 
Groups That Can be Detected With an ~80% Probability  and a Two -Sided 
Significance Level of 0.05 Postvaccination 2
True Incidence Rate of Adverse 
Events in the Control Group 
(Group 2)True Incidence Rate of Adverse 
Events in the Investigational 
Group (Group 1)Detectable Percentage Point 
Difference in Incidence Rates 
of Adverse Events
N=285 N=285
1% 5.0% 4.0
2% 6.8% 4.8
5% 11.4% 6.4
10% 18.1% 8.1
15% 24.3% 9.3
20% 30.2% 10.2
30% 41.2% 11.[ADDRESS_205444] (with a nominal 95% CI) for the primary  
immunogenicit y endpoints will be estimated and may be plotted within each category  of the 
following classification variables:
Sex (female, male)
Race 
  04S63N 
  055D6R
Product:   V210 57
Protocol/Amendment No.: A03-[ADDRESS_205445] Name [CONTACT_176023]34 
processbSingle 0.5 mL dose suspension for subcutaneous injection after 
reconstitution
Varicella Virus Vaccine Livea,b([ADDRESS_205446])Single 0.5 mL dose suspension for subcutaneous injection after 
reconstitution
Measles, Mumps, and Rubella Virus 
Vaccine Liveb,cSingle 0.5 mL dose suspension for subcutaneous injection after 
reconstitution
Sterile Diluent for Reconstitution of [COMPANY_006] 
Live Virus Vacc ines (Sterile Water)0.7 mL sterile solution for reconstitution
aVaricella Virus Vaccine Live = VARIVAX™ .
bPotency conforms to product standards as stated in the respective product insert s.
cMeasles, Mumps, and Rubella Virus Vaccine Live = M -M-R™ II .
Packaging and Labeling Information 9.2
Clinical supplies will be affixed with a clinical label in accordance with regulator y 
requirements.
Blinded, single -dose vials of VARIVAX™ PE34 process and VARI VAX™ ([ADDRESS_205447]) will be supplied to the clinic al sites. Open -label, single -dose vials of M -
M-R™ II and Sterile Diluent for reconstitution will be supplied to the clinical sites.  No 
subject- specific kitting is required. 
  04S63N 
  055D6R
Product:   V210 58
Protocol/Amendment No.: A03-[ADDRESS_205448]-2017
ConfidentialClinical Supplies Disclosure 9.3
The emergency  unblinding call center will use the treatment/ randomization schedule for the 
trial to unblind subjects and to unmask vaccine identity .  In the event that the emergency  
unblinding call center is not available for a given site in this trial, the central electronic 
treatment allocation/ randomizati on system (IVRS/I WRS) should be used in order to unblind 
subjects and to unmask treatment/vaccine identity . The Sponsor will notprovide random 
code/disclosure envelopes or lists with the clinical supplies .
Storage and Handling Requirements 9.[ADDRESS_205449]/Destruction/ Returns and Reconciliation 9.[ADDRESS_205450]/destruction procedure is documented .
Standard Policies 9.[ADDRESS_205451] access to a central electronic treatment 
allocation/ randomization system (IVRS/I WRS system) to allocate subjects, to assign vaccine
to subjects and to manage the distribution of clinical supplies. Each person accessing the 
IVRS system must be assigned an individual unique PIN.  They must use only their assigned 
PIN to access the sy stem, and they  must not share their assigned PIN with any one.
10.[ADDRESS_205452], ethics review committ ee (IRB/ERC) or similar 
or expert committee; affiliated institution and employ ees, only under an appropriate 
understanding of confidentiality  with such board or committee, affiliated institution and  
  04S63N 
  055D6R
Product:   V210 59
Protocol/Amendment No.: A03-[ADDRESS_205453] Records 10.1.2
By [CONTACT_12570], the investigator agrees that the Sponsor ( or Sponsor representative), 
IRB/ERC, or regulatory  authority  representatives may consult and/or copy  trial documents in 
order to verify  worksheet/case report form data.  By [CONTACT_17317], the subject 
agrees to this process.  If trial documents w ill be photocopi[INVESTIGATOR_75311]/case report form information, the subject will be identified by [CONTACT_19494]; 
full names/initials will be masked prior to transmission to the Sponsor.
By [CONTACT_12570], the investigat or agrees to treat all subject data used and disclosed in 
connection with this trial in accordance with all applicable privacy laws, rules and 
regulations.
Confidentiality of Investigator Information 10.1.[ADDRESS_205454] to the investigator, and all subinvestigators and trial site personnel, 
may be used and disclosed for trial management purposes, as part of a regulatory  
submissions, and as required b y law.  This inf ormation may  include:
1.name, address, telephone number and e -mail address;
2.hospi[INVESTIGATOR_26342];
3.curriculum vitae or other summary  of qualifications and credentials; and
4.other professional documentation.
Consistent with the purposes described above, this information may be transmitted to the 
Sponsor, and subsidiaries, affiliates and agents of the Sponsor, in your country  and other 
countries, including countries that do not have laws protecting such information.  
Additio nally , the investigator’s name [CONTACT_26407] [CONTACT_75387].  By [CONTACT_12570], the investigator expressly  consents to these uses and 
disclosures.
If this is a multicenter trial, in order to facilitate contact [CONTACT_26387], the Sponsor 
may share an investigator’s name [CONTACT_3669] [CONTACT_26388]. 
  04S63N 
  055D6R
Product:   V210 60
Protocol/Amendment No.: A03-[ADDRESS_205455]-2017
ConfidentialConfidentiality of IRB/IEC Info rmation 10.1.[ADDRESS_205456] the name [CONTACT_19525]/IEC that reviews and 
approves this trial.  The Sponsor is also required to document that each IRB/IEC meets 
regulatory  and ICH GCP requirements by [CONTACT_26389]/IEC members and to make these records available for 
regulatory  agency  review upon request b y those agencies.
Compliance with Financial Disclosure Requirements 10.2
Financial Disclosure requirements are outlined in the US Food and Drug Administration 
Regulations, Financial Disclosure by [CONTACT_6230] (21 CFR Part 54).  It is the 
Sponsor's responsibility to determine, based on these regulations, whether a request for 
Financial Disclosure information is required.   It is the investigator's/subinvestigator's 
responsibility  to comply  with any  such request.  
The investigator/subinvestigator(s) agree, if requested by [CONTACT_19489] 21 
CFR Part 54, to provide his/her financial interests in and/or arrang ements with the Sponsor to 
allow for the submission of complete and accurate certification and disclosure statements.  
The investigator/subinvestigator(s) further agree to provide this information on a 
Certification/Disclosure Form, commonly  known as a financial disclosure form, provided by 
[CONTACT_1034] . The investigator/subinvestigator(s) also consent to the transmission of this 
information to the Sponsor in the [LOCATION_002] for these purposes.  This may involve the 
transmission of information to countries that do not have laws protecting personal data.
Compliance with Law, Audit and Debarment 10.[ADDRESS_205457] the trial in an efficient and 
diligent manner and in conformance with this protocol; generall y accepted s tandards of Good 
Clinical Practice (e.g., International Conference on Harmonization of Technical 
Requirements for Registration of Pharmaceuticals for Human Use Good Clinical Practice: 
Consolidated Guideline and other generally  accepted standards of good cl inical practice); and 
all applicable federal, state and local laws, rules and regulations relating to the conduct of the 
clinical trial.
The Code of Conduct, a collection of goals and considerations that govern the ethical and 
scientific conduct of clinica l investigations sponsored by  [CONTACT_44873], is provided in Section 12.[ADDRESS_205458] for Clinical Trials .
The investigator also agrees to allow monitoring, audits, IRB/IEC review and regulatory  
authority  inspection of trial- related documents and proced ures and provide for direct access 
to all trial -related source data and documents.
The investigator agrees not to seek reimbursement from subjects, their insurance providers or 
from government programs for procedures included as part of the trial reimburse d to the 
investigator b y the Sponsor. 
  04S63N 
  055D6R
Product:   V210 61
Protocol/Amendment No.: A03-[ADDRESS_205459]-2017
ConfidentialThe investigator shall prepare and maintain complete and accurate trial documentation in 
compliance with Good Clinical Practice standards and applicable federal, state and local 
laws, rules and regulations; and, for each subject participating in the trial, provide all data, 
and, upon completion or termination of the clinical trial, submit any other reports to the 
Sponsor as required by  [CONTACT_75389].
Trial documentation will be promptly  and fully disclosed to the Sponsor by [CONTACT_26391], 
copy ing, review and audit at reasonable times by [CONTACT_176017].  The investigator agrees to promptly  take any  reasonable steps that are 
requested b y the Sponsor as a result of an audit to cure deficiencies in the trial documentation 
and worksheets/case report forms.
The investiga tor must maintain copi[INVESTIGATOR_90047].  This 
documentation includes, but is not limited to, the protocol, worksheets/case report forms, 
advertising for subject participation, adverse event reports, subject source data, 
correspondence with regulatory  authorities and IRBs/ERCs, consent forms, investigator’s 
curricula vitae, monitor visit logs, laboratory  reference ranges, laboratory  certification or 
quality  control procedures and laboratory  director curriculum vitae.  By  [CONTACT_12570], 
the investigator agrees that documentation shall be retained until at least [ADDRESS_205460] consult 
with and obtain written approval b y the Sponsor prior to destro ying trial and/or subject files.  
ICH Good Clinical Practice 
guidelines recommend that the investigator inform the subject’s 
primary  physician about the subject’s participation in the trial if the subject has a primary  
physician and if the subject agrees to the primary  physician being informed.
The investigator will promptly  inform the Sponsor of any regulatory  authority  inspection 
conducted for this trial.
Persons debarred from conducting or working on clinical trials by [CONTACT_176018] d to conduct or work on this Sponsor’s trials.  The investigator 
will immediately  disclose in writing to the Sponsor if any person who is involved in 
conducting the trial is debarred or if any proceeding for debarment is pending or, to the best 
of the inve stigator’s knowledge, threatened. 
  04S63N 
  055D6R
Product:   V210 62
Protocol/Amendment No.: A03-[ADDRESS_205461]-2017
ConfidentialIn the event the Sponsor prematurel y terminates a particular trial site, the Sponsor will 
promptly  notify  that trial site’s I RB/IEC.
According to European legislation, a Sponsor must designate an overall coordinating 
inves tigator for a multi -center trial (including multinational).  When more than one trial site 
is open in an EU country, [COMPANY_006], as the Sponsor, will designate, per country , a national 
principal coordinator (Protocol CI), responsible for coordinating the work of the principal 
investigators at the different trial sites in that Member State, according to national 
regulations.  For a single -center trial, the Protocol CI is the principal investigator.  In 
addition, the Sponsor must designate a principal or coordinat ing investigator to review the 
trial report that summarizes the trial results and confirm that, to the best of his/her 
knowledge, the report accuratel y describes the conduct and results of the trial [Clinical Study  
Report (CSR) CI].  The Sponsor may consid er one or more factors in the selection of the 
individual to serve as the Protocol CI and or CSR CI (e.g., availabilit y of the Protocol/CSR 
CI during the anticipated review process, thorough understanding of clinical trial methods, 
appropriate enrollment of subject cohort, timely achievement of trial milestones).  The 
Protocol CI  must be a participating trial investigator.
Compliance with Trial Registration and Results Posting Requirements 10.[ADDRESS_205462] (FDAAA) of 2007 
and the European Medicines Agency  (EMA) clinical trial Directive 2001/20/EC, the Sponsor 
of the trial is solely  responsible for determining whether the trial and its results are subject to 
the requirements for submission to http://www.clinic altrials.gov, 
www.clinicaltrialsregister.eu or other local registries.  [COMPANY_006], as Sponsor of this trial, will 
review this protocol and submit the information necessary  to fulfill these requirements. 
[COMPANY_006] entries are not limited to FDAAA or the EMA clinica l trial directive mandated trials.  
Information posted will allow subjects to identify  potentiall y appropriate trials for their 
disease conditions and pursue participation by [CONTACT_3379] a central contact [CONTACT_176019].  
By [CONTACT_12570], the investigator acknowledges that the statutory  obligations under 
FDAAA, the EMA clinical trials directive or other locall y mandated registries are that of the 
Sponsor and agrees not to submit any information about this trial or its results to those 
registries.
Quality Management System 10.[ADDRESS_205463] operating procedures (SOPs) to ensure that trials are conducted and 
data are generated, documented, and reported in compliance with the protocol, accepted 
standards of Good Clinical Practice, and all applicable federal , state, and local laws, rules and 
regulations relating to the conduct of the clinical trial. 
  04S63N 
  055D6R
Product:   V210 63
Protocol/Amendment No.: A03-[ADDRESS_205464] data.  By [CONTACT_12570], the investigator acknowledges that his/her 
electronic signature [CONTACT_75412] y binding equivalent of a written signature.  By [CONTACT_75393] g 
his/her electronic signature, the investigator confirms that all recorded data have been 
verified as accurate.
Detailed informat ion regarding Data Management procedures for this protocol will be 
provided separatel y.
Publications 10.7
This trial is intended for publication, even if terminated prematurel y. Publication may include 
any or all of the following: posting of a synopsis online, abstract and/or presentation at a 
scientific conference, or publication of a full manuscript.  The Sponsor will work with the 
authors to submit a manuscript describing trial results within [ADDRESS_205465]'s last visit for the 
primary  outcome, [ADDRESS_205466] 
marketing (dispensed, administered, delivered or promoted), whichever is later.
These timelines may be extended for products that are not yet marketed, if additional time is 
needed for analysis, to protect intellectual property , or to compl y with confidentiality 
agreements with other parties.  Authors of the primary  results manuscript will be provided 
the complete results from the Clinical Study  Report, subject to the confidentiality  agreement. 
When a manuscript is submitted to a biomedical journal, the Sponsor's policy  is to also 
include the protocol and statistical analy sis plan to facilitate the peer and editorial review of 
the manuscript.  If the manuscript is subsequently accepted for publication, the Sponsor will 
allow the journal, if it so desires, to post on its website the key sections of the protocol that 
are releva nt to evaluating the trial, specifically  those sections describing the trial objectives 
and hypotheses, the subject inclusion and exclusion criteria, the trial design and procedures, 
the efficacy  and safet y measures, the statistical analy sis plan, and any  amendments relating to 
those sections.  The Sponsor reserves the right to redact proprietary information.
For multicenter trials, subsequent to the multicenter publication (or after public disclosure of 
the results online at www.clinicaltrials.gov if a multicenter manuscript is not planned), an 
investigator and his/her colleagues may publish their data independentl y.  In most cases, 
publication of individual trial site data does not add value to complete multicenter results, 
due to statistical concerns.  Inrare cases, publication of single trial site data prior to the main 
paper may be of value.  Limitations of 
single trial site observations in a multicenter trial 
should alway s be described in such a manuscript. 
  04S63N 
  055D6R
Product:   V210 64
Protocol/Amendment No.: A03-[ADDRESS_205467]-2017
ConfidentialAuthorship credit should be based on 1) subst antial contributions to conception and design, 
or acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising 
it critically  for important intellectual content; and 3) final approval of the version to be 
published. Authors must meet conditions 1, [ADDRESS_205468] also been made to all three of the preceding authorship criteria.  Although 
publicati on planning may  begin before conducting the trial, final decisions on authorship and 
the order of authors’ names will be made 
based on participation and actual contributions to 
the trial and writing, as discussed above. The first author is responsible for defending the 
integrit y of the data, method(s) of data anal ysis and the scientific content of the manuscript.
The Sponsor must have the opportunity  to review all proposed abstracts, manuscripts or 
presentations regarding this trial 45days prior to submiss ion for publication/presentation. 
Any information identified by [CONTACT_26395]; this confidentiality  does not include efficacy  and safety  results. Sponsor review 
can be expedited to meet publication timeline s. 
  04S63N 
  055D6R
Product:   V210 65
Protocol/Amendment No.: A03-[ADDRESS_205469] OF REFERENCES
[1] Wharton M. The epi[INVESTIGATOR_175987] -zoster virus infections. Infect Dis Clin 
North Am 1996;10(3):571 -81.
[2] Galil K, Brown C, Lin F, Seward J. Hospi[INVESTIGATOR_175988], 1988 to 1999.[Article]. Pediatr I nfect Dis J 2002;21(10):931 -4.
[3] Mey er PA, Seward JF, Jumaan AO, Wharton M. Varicella mortality : trends before 
vaccine licensure in the [LOCATION_002], 1970- 1994. J I nfect Dis 2000;182:383 -90.
[4] Kuter BJ, Weibel RE, Guess H, Matthews H, Morto n DH, Neff BJ, et al. Oka/[COMPANY_006] 
varicella vaccine in healthy  children:  final report of a 2-year efficacy  study and 7-
year follow -up studies. Vaccine 1991;9(9):643
-7.
[5] Guris D, Jumaan AO, Mascola L, Watson BM, Zhang JX, Chaves SS, et al. 
Changing varic ella epi[INVESTIGATOR_175989]-[LOCATION_002], 1995-
2005. J I nfect Dis 2008;197(Suppl 2):S71 -S75.
[6] Luman ET, Ching PLYH, Jumaan AO, Seward JF. Uptake of varicella vaccination 
among young children in the [LOCATION_002]: A success story  in eliminating racial and 
ethnic disparities. Pediatr 2006;117(4):999-1008.
[7] Zhou F, Harpaz R, Jumaan AO, Winston CA, Shefer A. Impact of Varicella 
Vaccination on Health Care Utilization. JAMA 2005;294(7):797 -
802.
[8] Centers for Disease Control. Prevent ion of varicella:  recommendations of the 
advisory  committee on immunization practices (ACI P). MMWR 2007;56(RR -4):1-
CE-4.
[9] Marin M, Zhang JX, Seward JF. Near elimination of varicella deaths in the US after 
implementation of the vaccination program. Pediatrics 2011;128:214-20.
[10] Baxter R, Ray P, Tran TN, Black S, Shinefield HR, Coplan PM, et al. Long-term 
effectiveness of varicella vaccine: A 14-year, prospective cohort study . Pediatrics 
2013;131(5):1 -8.
[11] Centers for Disease Control and Preve ntion. Recommended immunization schedules 
for persons aged 0-- 18 years---[LOCATION_002], 2007. MMWR 2007;55(51):Q1 -Q4.
[12] White CJ, Kuter BJ, Ngai A, Hildebrand CS, Isganitis KL, Patterson CM, et al. 
Modified cases of chickenpox after varicella vaccinati on: correlation of protection 
with antibody  response. Pediatr Infect Dis J 1992;11(1):[ADDRESS_205470]:   V210 66
Protocol/Amendment No.: A03-[ADDRESS_205471]-2017
Confidential[13] Keller PM, Lonergan K, Neff BJ, Morton DA, Ellis RW. Purification of individual 
varicella -zoster virus (VZV) glycoproteins gpI, gpII, and gpI[INVESTIGATOR_175990]-specific antibodies. J Virol Methods 
1986;14:177 -88.
[14] Wasmuth EH, Miller WJ. Sensitive enzyme-linked immunosorbent assay  for 
antibody  to varicella -zoster virus using purified VZV glycoprotein antigen. J Med 
Virol 1990;32:189-93.
[15] Provost PJ, Krah DL, Kuter BJ, Morton DH, Schofield TL, Wasmuth EH, et al. 
Antibody  assays suitable for assessing immune responses to live varicella vaccine. 
Vaccine 1991;9:111-6.
[16] Krah DL, Cho I, Schofield T, Ellis RW. Comparison of gpELISA and neutralizing 
antibody  responses to Oka/[COMPANY_006] live varicella vaccine (VARIVAX®) in children 
and adults. Vaccine 1997;15(1):61-4.
[17] Miettinen O, Nurminen M. Comparative analysis of two rates. Statistics in Medicine 
1985;4:213-26.
[18] Collett D. Statistical inference for binary  data. In: Collett D, ed. Modelling Binary  
Data. [LOCATION_001]: Chapman & Hall, 1999:17-42. 
  04S63N 
  055D6R
Product:   V210 67
Protocol/Amendment No.: A03-[ADDRESS_205472] for Clinical Trials 12.1
[COMPANY_006] *
Code of Conduct for Clinical Trials
I. Introduction
A. Purpose
[COMPANY_006], through its subsidiaries, conducts clinical trials worldwide to evaluate the safety and effectiveness of our 
products. As such, we are committed to designing, implementing, conducting, analyzing and reporting these trials in 
compliance with the highest ethical and scientific standards. Protection of subject safety is the overriding concern in 
the design of clinical trials. In all cases, [COMPANY_006] clinical trials will be conducted in compliance with local and/or 
national regulations and in accorda nce with the ethical principles that have their origin in the Declaration of Helsinki. 
B. Scope
Such standards shall be endorsed for all clinical interventional investigations sponsored by [CONTACT_75395] (parties) employed for their execution (e.g., contract research organizations, collaborative research efforts). This 
Code is not intended to apply to trials which are observational in nature, or which are retrospective. Further, this Code 
does not apply to investigator -initiated trial s which are not under the control of [COMPANY_006].
II.Scientific Issues
A. Trial Conduct
1.Trial Design
Except for pi[INVESTIGATOR_19354], clinical trial protocols will be hypothesis -driven to assess safety, efficacy 
and/or pharmacokinetic or pharmacodynami c indices of [COMPANY_006] or comparator products.  Alternatively, [COMPANY_006] may 
conduct outcomes research trials, trials to assess or validate various endpoint measures, or trials to determine 
subject preferences, etc.  
The design (i.e., subject population, duration, statistical power) must be adequate to address the specific purpose 
of the trial.  Research subjects must meet protocol entry criteria to be enrolled in the trial. 
2.Site Selection
[COMPANY_006] selects investigati ve sites based on medical expert[INVESTIGATOR_18700], access to appropriate subjects, adequacy of facilities 
and staff, previous performance in [COMPANY_006] trials, as well as budgetary considerations.  Prior to trial initiation, sites 
are evaluated by [CONTACT_90093] t he ability to successfully conduct the trial.
3.Site Monitoring/Scientific Integrity
Trial sites are monitored to assess compliance with the trial protocol and general principles of Good Clinical 
Practice.  [COMPANY_006] reviews clinical data for accuracy, comple teness and c onsistency. Data are verified versus source 
documentation according to standard operating procedures.  Per [COMPANY_006] policies and procedures, if fraud, 
misconduct or serious GCP -non-Compliance are suspected, the issues are promptly investigated. When necessary, 
the clinical site will be closed, the responsible regulatory authorities and ethics review committees notified and 
data disclosed accordingly. 
B. Publication and Authorship
To the extent scientifically appropriate, [COMPANY_006] seeks to publish theresults of trials it conducts.  Some early phase or 
pi[INVESTIGATOR_26346] -generating rather than hypothesis testing.  In such cases, publication of 
results may not be appropriate since the trial may be underpowered and the analyses complicated by [CONTACT_75397].
[COMPANY_006]’s policy on authorship is consistent with the requirements outlined in the ICH-Good Clinical Practice 
guidelines. In summary, authorship should reflect significant contribution to the design and conduc t of the trial, 
performance or interpretation of the analysis, and/or writing of the manuscript.  All named authors must be able to 
defend the trial results and conclusions.  [COMPANY_006] funding of a trial will be acknowledged in publications.  
  04S63N 
  055D6R
Product:   V210 68
Protocol/Amendment No.: A03-[ADDRESS_205473] Prot ection
A.IRB/ERC review
All clinical trials will be reviewed and approved by [CONTACT_75398]/ERC before being initiated at each site.  
Significant changes or revisions to the protocol will be approved by [CONTACT_1201]/ERC prior to implementation, except that 
changes required urgentl y to protect subject safety and well-being may be enacted in anticipation of IRB/ERC 
approval. For each site, the IRB/ERC and [COMPANY_006] will approve the subject informed consent form. 
B.Safety
The guiding principle in decision -making in clinical trials is that subject welfare is of primary importance.  Potential 
subjects will be informed of the risks and benefits of, as well as alternatives to, trial participation. At a minimum, trial 
designs will take into account the local standard of care.  Subjects are ne ver denied access to appropriate medical care 
based on participation in a [COMPANY_006] clinical trial. 
All participation in [COMPANY_006] clinical trials is voluntary.  Subjects are enrolled only after providing informed consent for 
participation.  Subjects may withdraw from a [COMPANY_006] trial at any time, without any influence on their access to, or 
receipt of, medical care that may otherwise be available to them.
C.Confidentiality
[COMPANY_006] is committed to safeguarding subject confidentiality, to the greatest extent possible. Unless required by [CONTACT_2371], 
only the investigator, Sponsor (or representative) and/or regulatory authorities will have access to confidential medical 
records that might identify the research subject by [CONTACT_2300].  
D.Genomic Research
Genomic Research will only beconducted in accordance with informed consent and/or as specifically authorized by 
[CONTACT_75399].
IV.Financial Considerations
A.Payments to Investigators
Clinical trials are time- and labor-intensive.  It is [COMPANY_006]’s policy to compensate investigat ors (or the sponsoring 
institution) in a fair manner for the work performe d in support of [COMPANY_006] trials.  [COMPANY_006] does not pay incentives to 
enroll subjects in its trials.  However, when enrollment is particularly challenging, additional payments may be made 
to compensate for the time spent in extra recruiting efforts.
[COMPANY_006] does not pay for subject referrals.  However, [COMPANY_006] may compensate referring physicians for time spent on 
chart review to identify potentially eligible subjects.
B.Clinical Research Fundi ng 
Informed consent forms will disclose that the trial is sponsored by [CONTACT_44873], and that the investigator or sponsoring 
institution is being paid or provided a grant for performing the trial.  However, the local IRB/ERC may wish to alter 
the wording of the disclosure statement to be consistent with financial practices at that institution.  As noted above, 
publications resulting from [COMPANY_006] trials will indicate [COMPANY_006] as a source of funding.
C.Funding for Travel and Other Requests
Funding of travel by [CONTACT_176020] (e.g.,to scientific meetings, investigator meetings, etc.) will be 
consistent with local guidelines and practices including, in the U.S., those established by [CONTACT_75401] (AMA). 
V. Investigator Commit ment
Investigators will be expected to review [COMPANY_006]’s Code of Conduct as an appendix to the trial protocol, and in signing 
the protocol, agree to support these ethical and scientific standards.
* In this document, "[COMPANY_006]" refers to [COMPANY_006] Sharp & Dohme Corp. andSchering Corporation, each of which is a 
subsidiary of [COMPANY_006] & Co., Inc.  [COMPANY_006] is known as MSD outside of the [LOCATION_002] and Canada.  As warranted by 
[CONTACT_74647], [COMPANY_006] also includes affiliates and subsidiaries of [COMPANY_006] & Co., Inc." 
  04S63N 
  055D6R
Product:   V210 69
Protocol/Amendment No.: A03-[ADDRESS_205474]-2017
ConfidentialCollection and Management of Specimens for Future Biomedical Research 12.2
1.Definitions
a.Biomarker:  A biological molecule found in blood, other body  fluids, or tissues that is a 
sign of a normal or abnormal process or of a condition or disease.  A biomarker may be 
used t o see how well the body  responds to a treatment for a disease or condition.1
b.Pharmacogenomics:  The investigation of variations of DNA and RNA characteristics as 
related to drug /vaccine response.2
c.Pharmacogenetics:  A subset of pharmacogenomics, phar macogenetics is the influence of 
variations in DNA sequence on drug /vaccine response.2
d.DNA:  Deox yribonucleic acid.
e.RNA:  Ribonucleic acid.
2.Scope of Future Biomedical Research
The specimens consented and/or collected in this trial as outlined in Section [IP_ADDRESS] –
Future Biomedical Research Samples will be used in various experiments to understand:
oThe biology  of how drugs/vaccines work
oBiomarkers responsible for how a drug/vaccine enters and is removed b y the body
oOther pathway s drugs/vaccines may  interact with
oThe biology  of disease
The specimen(s) may be used for future assay  development and/or drug/vaccine 
development.
It is now well recognized that information obtained from study ing and testing clinical 
specimens offers unique opportunities to enhance our understanding of how individuals 
respond to drugs /vaccines , enhance our understanding of human disease and ultimately 
improve public health through development of novel treatments targeted to populations 
with the greatest need.  All specimens will be used by [CONTACT_75402] .
3.Summary of Procedures for Future Biomedical Research
a.Subjects for Enrollment
All subjects enrolled in the clinical trial will be considered forenrollment in the 
Future Biomedical Research sub -trial.
b.Informed Consent
Informed consent for specimens (i.e., DNA, RNA, protein, etc.) will be obtained 
during screening for protocol enrollment from all subjects or legal guardians, at a trial 
visit by [CONTACT_90094].  Informed consent for Future 
Biomedical Research should be presented to the subjects on the visi t designated in the 
trial flow chart .  If delayed, present consent at next possible Subject Visit.   Consent 
forms signed by [CONTACT_75404].   
  04S63N 
  055D6R
Product:   V210 70
Protocol/Amendment No.: A03-[ADDRESS_205475]-2017
ConfidentialA template of each trial site’s approved informed consent will be stored in the 
Sponsor’s clinical document repository .
c.eCRF Documentation for Future Biomedical Research Specimens
Documentation of subject consent for Future Biomedical Research will be captured in 
the electronic Case Report Forms (eCRFs). Any specimens for which such an 
informed consent cannot be verified will be destroy ed.
d.Future Biomedical Research Specimen(s)
Collection of specimens for Future Biomedical Research will be performed as 
outlined in the trial flow chart. In general, if additional blood specimens are being 
collected for Future Biomedical Research, these will usually  be obtained at a time 
when the subject is having blood drawn for other trial purposes.
4. C onfidential Subject Information for Future Biomedical Research 
In order to optimize the research that can be conducted with Future Biomedical Research 
specimens, it is critical to link subject' clinical information with future test results. In fact 
little or no research can be conducted without connecti ng the clinical trial data to the 
specimen. The clinical data allow specific analy ses to be conducted. Knowing subject 
characteristics like gender, age, medical history  and treatment outcomes are critical to 
understanding clinical context of analytical results.
To maintain privacy  of information collected from specimens obtained for Future 
Biomedical Research, the Sponsor has developed secure policies and procedures. All 
specimens will be single -coded per ICH E15 guidelines as described below . 
At the clinical trial site, unique codes will be placed on the Future Biomedical Research 
specimens.  This code is a random number which does not contain any personall y 
identify ing information embedded within it. The link (or key) between subject identifie rs 
and this unique code will be held at the trial site.  No personal identifiers will appear on 
the specimen tube.  
5.Biorepository Specimen Usage
Specimens obtained for the Sponsor will be used for analyses using good scientific 
practices.  Anal yses utilizing the Future Biomedical Research specimens may be 
performed by [CONTACT_1034] , or an additional third party (e.g., a university  investigator) 
designated by [CONTACT_1034] . The investigator conducting the analy sis will follow the 
Sponsor’s privacy  and confid entiality  requirements. Any contracted third party  analyses 
will conform to the specific scope of anal ysis outlined in this sub- trial. Future Biomedical 
Research specimens remaining with the third party  after specific analy sis is performed 
will be reported to the Sponsor .
6. Withdrawal From Future Biomedical Research 
Subjects may withdraw their consent for Future Biomedical Research and ask that their 
biospecimens not be used for Future Biomedical Research.   Subjects may withdraw 
consent at any time by [CONTACT_59554] [INVESTIGATOR_75306]. If medical 
records for the main trial are still available, the investigator will contact [CONTACT_90095] ([EMAIL_1250]).  
  04S63N 
  055D6R
Product:   V210 71
Protocol/Amendment No.: A03-[ADDRESS_205476]'s specimens will be flagged in the biorepository and restricted 
to main study  use only. If specimens were collected from study  participants specificall y 
for Future Biomedical Research, these specimens will be removed from the biorepository  
and destro yed. Docu mentation will be sent to the investigat or confirming withdrawal 
and/or destruction, if applicable. It is the responsibility  of the investigator to inform the 
subject of completion of the withdrawal and/or destruction, if applicable.  Any analyses 
in progr ess at the time of request for withdrawal/destruction or already  performed prior to 
the request being received by [CONTACT_75406]. No new analy ses would be generated after the request is 
received.
In the event that the medical records for the main trial are no longer available (e.g., if the 
investigator is no longer required by [CONTACT_75407]) or the specimens have been completel y anony mized, there will no longer be a 
link between the subject’s personal information and their specimens. In this situation, the 
request for withdrawal of consent and/or destruction cannot be processed.
7. Retention of Specimens 
Future Biomedical Research specimens will be stored in the biorepository  for potential 
analysis for up to [ADDRESS_205477] results are accessible only to the 
authorized Sponsor representatives and the designated trial administrator research 
personnel and/or collaborators. Database user authentication is highly secure, and is 
accomplished using network securit y policies and practices based on international 
standards to protect aga inst unauthorized access.
9.
Reporting of Future Biomedical Research Data to Subjects
No information obtained from exploratory  laboratory  studies will be reported to the 
subject, family , or physicians. Principle reasons not to inform or return results to the 
subject include: Lack of relevance to subject health, limitations of predictive capability , 
and concerns regarding misinterpretation.
If important research findings are discovered, the Sponsor may publish results, present 
results in national meetings, and make results accessible on a public website in order to 
rapi[INVESTIGATOR_90048].  Subjects will not be identified by  
  04S63N 
  055D6R
Product:   V210 72
Protocol/Amendment No.: A03-[ADDRESS_205478] data 
privacy  concerns.  Data privacy  risks are largely  limited to rare situations involving 
possible breach of confidentiality .  In this highly unlikely  situation there is risk that the 
informat ion, like all medical information, may  be misused.
12.Questions
Any questions related to the future biomedical research should be e
-mailed directl y to 
[EMAIL_1250].
13.References
1.
National Cancer Institute: http://www.cancer.gov/dictionary /?searchTxt=biomarker
2.International Conference on Harmonization: DEFIN ITIO NS FOR GENOMIC 
BIOMARKERS, PHARMACOGENOMICS, PHARMACOGENETICS, GENOMIC 
DATA AND SAMPL E CODING CATEGORIES - E15; 
http://www.ich.org/LOB/media/MEDIA3 383.pdf
3.Industry  Pharmacogenomics Working Group. Understanding the Intent, Scope and 
Public Health Benefits of Exploratory  Biomarker Research: A Guide for IRBs/IECs 
and Investigational Site Staff. Available at http://i -pwg.org/
4.Industry  Pharmacogenom ics Working Group. Pharmacogenomics Informational 
Brochure for IRBs/IECs and Investigational Site Staff. Available at http://i -pwg.org/ 
  04S63N 
  055D6R
Product:   V210 73
Protocol/Amendment No.: A03-[ADDRESS_205479]-2017
ConfidentialApproximate Blood Volumes Collected by [CONTACT_176021] 12.3
Trial Visit Visit 1 Visit 2 Visit 3 Visit 4
Blood for immunogenicity testing 3 3 — —
Expected total (mL) 3 3 — — 
  04S63N 
  055D6R
Product:   V210 74
Protocol/Amendment No.: A03-[ADDRESS_205480]-2017
ConfidentialScripted Questionnaire to Be Used by [CONTACT_176022] 12.4
Experience and Medically Attended Adverse Event Information
The following script is to be used at the Phone Call at Day 271 (180 days after Dose 2) in 
order to probe for any serious adverse experiences and medicall y attended adverse events 
that were not previousl y reported by [CONTACT_423]'s parent/ legall y acceptable representative 
from Vis it4 (Day 133) thr ough Day  271.
It is the responsibility  of the Investigator to carefully  assess the information and make a 
determination whether the adverse experience meets one or more criteria for being reported 
as a serious adverse experience. Serious adverse experience s and medically  attended adverse 
events identified through the interview process should be reported to the Sponsor /Sponsor
Representative.
Questionnaire :
Since the last visit,
1.Has your child been admitted to a hospi[INVESTIGATOR_307]?
2.Has your child experienced a life-threatening epi[INVESTIGATOR_175991] a health care provider’s office?
3.Has your child seen your doctor, nurse, or health care provider for any other reason 
other than a well -child visit?
4. Did your child have any medical conditions before you agreed to participate in the 
trial that have become worse or have required more frequent visits to a health care 
provider since the last visit?
5.Has your child developed cancer?
6.Has your child developed a new medical condition that I  am not aware of?
If the answer to any of the questions above is “yes”, the interviewer will determine if the 
event is a serious adverse experience or a medically  attended event and if so, will gather all 
related information and tra nscrib e onto the appropriate eCRFs.
For each serious adverse experience that is identified through the interview process, 
information from all available sources, including subject /legally  acceptable representative
report, subject medical records, hospi[INVESTIGATOR_44458] , and death certificate should be 
sought to provide a complete description of the adverse experience. All pertinent information 
must be recorded in the database and retained in the subject’s file including, but not limited 
to:
Serious adverse experience term
Onset date
Causality
Outcome 
  04S63N 
  055D6R
Product:   V210 75
Protocol/Amendment No.: A03-[ADDRESS_205481]-2017
ConfidentialThe seriousness criteria that the adverse experience met:
−death 
−caused hospi[INVESTIGATOR_169016]
−persistent or significant disability
− life-threatening adverse experience
−cancer
−due to an overdose
−congenital anomal y
− other medical adverse experience
Hospi[INVESTIGATOR_175992]
Hospi[INVESTIGATOR_166159]
Concomitant medications/vaccinations or changes in concomitant medications 
associated wi th the serious adverse experience
Concurrent conditions
Other medical history
Procedures associated with the serious adverse experience
Laboratory  results 
  04S63N 
  055D6R
Product:   V210 76
Protocol/Amendment No.: A03-[ADDRESS_205482] of Abbreviations and Definitions of Terms 12.5
Term Definition
ACIP Advisory  Commi ttee on Immunization Practices
AE adverse event or adverse experience (used interchangeably)
ASaT All Subjects As Treated
CI confidence interval
CID component identification number
CSR clinical study report
DOD delta optical density
DTaP Diphtheria, Te tanus, and Acellular Pertussis
DNA deox yribonucleic acid
ECI event of clinical interest
eCRF electronic case report form
EDC electronic data capture
EU European Union
FDA Food and Drug Administration
FSA full analysis set
GCP Good Clinical Practice
GMFR geometric mean fold rise
GMT geometric mean titer
gp glycoprotein
gpELISA glycoprotein enzyme-linked immuno sorbent a ssay
Hib Haemophilus influenzae type b
HIV human immunodeficiency virus
HZ herpes zoster
IgG immunoglobulin G
IPV inactivated poliovirus
IRB institution alreview board
IVRS interactive voice response system
IWRS integrated web response sy stem
M M -R™ II measles, mumps, and ru bella virus vaccine live, [COMPANY_006] 
  04S63N 
  055D6R
Product:   V210 77
Protocol/Amendment No.: A03-[ADDRESS_205483]-2017
ConfidentialTerm Definition
OD optical density
PP Per-p rotocol Population
PRO patient -reported outcome
ProQuad™ measles, mumps, rubella, and varicella virus vaccine live, [COMPANY_006]
SD standard deviation
SOC system organ class
SOP standard operating p rocedure
TCC tissue culture control
VARIVAX™ varicella virus vaccine live (Oka /[COMPANY_006] ); A210
eVRC electronic v accination report card
VZV varicella z oster virus
WHO World Health Organization
ZOSTAVAX™ zoster vaccine live, [COMPANY_006] 
  04S63N 
  055D6R
Product:   V210 78
Protocol/Amendment No.: A03-[ADDRESS_205484]-2017
Confidential13.0 SIGNATURES
Sponsor's Representative 13.[ADDRESS_205485] this clinical trial in accordance with the design outlined in this protocol 
and to abide by [CONTACT_19373] (including other manuals and documents 
referenced from this protocol).  I  agree to conduct the trial in accordance with generally 
accepte d standards of Good Clinical Practice.  I also agree to report all information or data in 
accordance with the protocol and, in particular, I agree to report any serious adverse events 
as defined in Section 7.0–TRIAL PROCEDURES (Assessing and Recording Adverse 
Events ).  I also agree to handle all clinical supplies provided by [CONTACT_26403].  I understand that information 
that identifies me will be used and disclosed as described inthe protocol, and that such 
information may be transferred to countries that do not have laws protecting such 
information.  Since the information in this protocol and the referenced Investigator’s 
Brochure is confidential, I understand that its disclosure to any third parties, other than those 
involved in approval, supervision, or conduct of the trial is prohibited.  I will ensure that the 
necessary  precautions are taken to protect such information from loss, inadvertent disclosure 
or access b y third parti es.
TYPED NAME
[CONTACT_26410] 
  04S63N 
  055D6R